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Lupus erythematosus (LE) is a chronic, heterogeneous autoimmune disorder with abnormal 
immune responses, including production of autoantibodies and immune complexes. Clinical 
presentations of the disease range from mild cutaneous manifestations to a more generalised 
systemic involvement of internal organs. Cutaneous (CLE) forms are further subclassified 
into discoid LE (DLE), subacute cutaneous LE (SCLE) and acute cutaneous lupus 
erythematosus (ACLE), and may later progress to systemic disease (SLE). Both genetic and 
environmental factors contribute to the disease, although the precise aetiology is still elusive. 
Furthermore, complex gene-gene or gene-environment interactions may result in different 
subphenotypes of lupus. The genetic background of CLE is poorly known and only a few 
genes are confirmed, while the number of robust genetic associations in SLE exceeds 30.  
 
The  aim  of  this  thesis  was  to  characterise  the  recruited  patients  (n=310)  clinically,  and  
identify genetic variants conferring susceptibility to cutaneous variants of LE. Given that 
cutaneous and systemic disease may share underlying genetic factors, putative CLE candidate 
genes for genotyping were selected among those showing strong evidence of association in 
SLE. The correlation between relevant clinical manifestations and risk genotypes was 
investigated in order to find specific subphenotype associations. In addition, epistatic 
interactions in SLE were studied. Finally, the role of tissue degrading matrix 
metalloproteinases (MMP) in LE tissue injury was explored. These studies were conducted in 
Finnish case-control and family cohort, and Swedish case-control cohort. 
 
The clinical picture of the patients in terms of cutaneous, haematological and immunological 
findings resembled that described in the contemporary literature. However, the proportion of 
daily smokers was very high supporting the role of smoking in disease aetiology. The results 
confirmed that, even though clinically distinct entities, CLE and SLE share predisposing 
genetic factors. For the first time it was shown that known SLE susceptibility genes IRF5 and 
TYK2 also increase the risk of CLE. A tendency toward gene-gene interaction between these 
genes was found in SLE. As a remarkable novel finding, it was observed that ITGAM 
polymorphisms associated even more strongly to DLE than SLE, and the risk estimates were 
substantially higher than those reported for SLE. Several other recently identified SLE 
susceptibility genes showed signs of good or modest association especially in DLE. 
Subphenotype analyses indicated possible associations to clinical features, but marginally 
significant results reflected lack of sufficient power for these studies. Thorough 
immunohistochemical analyses of several MMPs demonstrated a role in epidermal changes 
and dermal tissue remodelling in diseased skin, and suggested that targeted action using 
selective MMP inhibitors may reduce lupus-induced damage in inflamed tissues. 
 
In  conclusion,  the  results  provide  an  insight  into  the  genetics  of  CLE  and  demonstrate  that  
genetic predisposition is at least in part shared between cutaneous and systemic variants of 
LE. This doctoral study has contributed IRF5, TYK2, ITGAM and several other novel genes to 




function of these genes in CLE pathogenesis warrants further studies. Furthermore, the results 
support the need of subphenotype analysis with sample sizes large enough to reveal possible 
specific disease associations in order to better understand the heterogeneous nature and 
clinical specificities of the disease. Comprehensive analysis of clinical data suggests that 







Lupus erythematosus (LE) on monimuotoinen krooninen autoimmuunisairaus, jonka kliininen 
kuva vaihtelee lievästä ihoon rajoittuvasta diskoidista (DLE) muodosta vakavaan, monia 
sisäelimiä vahingoittavaan systeemiseen (SLE) muotoon. LE:lle on tyypillistä vasta-aineiden 
tuotto elimistön omia kudoksia vastaan. Täsmällistä sairastumismekanismia ei tunneta, mutta 
perintötekijöiden ja ympäristötekijöiden tiedetään vaikuttavan sairastumisalttiuteen. 
Sairastuneet ovat usein nuoria naisia. Ihomuutokset aiheuttavat sosiaalista haittaa ja potilaiden 
elämänlaatu on heikentynyt. Parantavaa hoitoa ei ole ja käytetyillä lääkkeillä on haitallisia 
sivuvaikutuksia. 
 
Iholupukselle altistavien geenien tutkiminen on ollut vähäistä, ja tutkimustulokset ovat 
ristiriitaisia. Vain muutaman geenin tiedetään varmasti lisäävän riskiä sairastua iholupukseen, 
kun taas SLE:n alttiusgeenejä tunnetaan yli 30. Lisäksi monimutkaiset geeni-geeni- ja geeni-
ympäristövuorovaikutukset saattavat vaikuttaa siihen, sairastuuko potilas iho- vai 
systeemiseen lupukseen.  
 
Tämän tutkimuksen tarkoituksena oli kuvata kerätyn potilasaineiston ihomuutoksia sekä 
immunologiaan ja verenkuvaan liittyviä muutoksia ja altistavia ympäristötekijöitä. 
Tutkimuksessa selvitettiin LE:n ihomuotojen geneettisiä tekijöitä ja mahdollisia geeni-geeni-
vuorovaikutuksia. Geneettisiin tutkimuksiin valitut geenit ja niiden polymorfiat olivat 
sellaisia, joiden tiedetään liittyvän vahvasti SLE:n sairastumisalttiuteen. Lisäksi tutkimme 
matriksin metalloproteinaasien (MMP) roolia kudosvaurioissa. Tutkimusaineistona käytettiin 
suomalaisia iholupuspotilaita (n=310) ja terveitä verrokkihenkilöitä (n=356), suomalaisia 
SLE-perheitä (n=192) ja ruotsalaista tapaus-verrokkiaineistoa (n=164+295). 
 
Suomalaisten potilaiden ihomuutokset sekä immunologiaan ja verenkuvaan liittyvät löydökset 
olivat samanlaisia kuin kirjallisuudessa aikaisemmin kuvatuilla potilailla. Huomattavan suuri 
osa potilaista tupakoi ensimmäisten oireiden ilmetessä. Geneettisissä tutkimuksissa 
osoitimme, että IRF5- ja TYK2-geenit lisäävät riskiä sairastua iholupukseen. Havaitsimme 
myös tilastollisesti merkitsevän interaktion näiden kahden geenin välillä SLE-potilaissa. 
Terveisiin verrokkihenkilöihin verrattuna ITGAM-geenin polymorfiat lisäsivät 
kolminkertaisesti riskiä sairastua DLE:hen. Myös muut hiljattain tunnistetut SLE:n 
alttiusgeenit assosioituivat iholupukseen. Kliinisten alatyyppien ja tutkittujen 
geenipolymorfioiden välillä havaittiin vain heikkoja assosiaatioita, mikä johtunee liian 
pienestä otoskoosta. Tutkimustulokset osoittivat, että lupuksen eri alatyyppien MMP-
ilmentymisprofiili on hyvin samankaltainen. Tämän perusteella voidaan ehdottaa, että MMP-
estäjien kohdennettu käyttö saattaa vähentää lupuksesta johtuvia kudosvaurioita 
tulehdusalueilla. 
 
Tässä tutkimuksessa saadut tulokset lisäävät tietoutta iholupuksen geneettisestä taustasta ja 
osoittavat, että lupuksen eri muodoilla on ainakin osittain yhteinen geneettinen pohja. Uutena 




assosioidu vain SLE:hen vaan myös iholupukseen. Näiden geenien vaikutusmekanismit 
iholupuksen synnyssä ovat toistaiseksi tuntemattomia. Sairauden monimuotoisuuden 
ymmärtämiseksi on tärkeää analysoida kliinisten erityispiirteiden ja geneettisten tekijöiden 
välistä yhteyttä. Riittävän iso otoskoko on kuitenkin edellytys luotettavien tulosten 
saamiseksi. Tupakointia voidaan pitää mahdollisena altistavana ympäristötekijänä, joka voi 






Lupus erythematosus (LE) is a heterogeneous autoimmune disease with a varying clinical 
course. Manifestations range from skin-restricted lesions to a multi-organ, systemic disease. 
From a clinical standpoint the disease is subdivided into discoid (DLE), subacute cutaneous 
(SCLE) and systemic (SLE) forms, all of which have their characteristic immunological and 
haematological stigmata. LE is a multifactorial disease, as both genetic and environmental 
factors contribute to disease onset. The molecular level pathogenesis is, however, poorly 
understood.  
 
Comprehensive descriptive surveys conducted in cutaneous lupus (CLE) patients are sparse 
and often confounded by patient misclassification. Furthermore, genetic ancestry may affect 
the presence of clinical manifestations. This emphasises the need to carefully verify recruited 
patients  both  clinically  and  genetically.  A  strong  genetic  component  similar  to  that  of  SLE  
may also underlie CLE. There are a few confirmed predisposing genes for DLE and SCLE 
including HLA, TNF-  and complement genes. Many genes outside the HLA region have 
shown signs of linkage or association, but their role needs to be confirmed. The genetic 
background of SLE has been extensively studied and over 30 genes have reached significant 
association. Many of these genes fall in key pathways implicated in disease pathogenesis. 
Epistasis, in other words, gene-gene interaction has been recognised for long but it has not 
been specifically addressed in LE. Subphenotype analysis may shed light on the 
overwhelming clinical variability of the disease, but attempts to perform these analyses have 
been unsuccessful, probably due to limited sample size and low statistical power. 
 
The central aim of this study was to attain a well-characterised group of CLE patients as the 
basis for genetic studies. For this purpose, over 300 patients with DLE, SCLE or SLE were 
recruited and evaluated. Clustering of autoimmune diseases in families and shared pathogenic 
features between CLE and SLE implicate that there may be common genes underlying disease 
progression. Therefore, we set out to genotype a group of genes previously implicated in SLE 





REVIEW OF THE LITERATURE 
 
1 Structure of the skin 
The skin is the largest and most complex organ of the human body and provides a protective 
interface between the organism and pathogens invading from the environment (Rao et al. 
1996). Skin consists of two compartments, namely the outer epidermis and the inner dermis 
(Vitellaro-Zuccarello 1997). The principle cells in the epidermis are keratinocytes that 
differentiate and migrate progressively through epidermal layers. These layers include the 
innermost proliferating basal layer (stratum basale); the spinous layer (stratum spinosum); the 
granular layer (stratum granulosum); and the outermost horny layer (stratum corneum). Three 
other types of cells are also present in the epidermis: antigen-presenting Langerhans cells, 
pigment-producing melanocytes and Merkel cells, which are mechanoreceptors. Beneath the 
epidermis lies the dermis, a dense connective tissue, where blood vessels are also located.  
 
2 Historical aspects of cutaneous lupus erythematosus 
The term lupus érythémateaux was introduced for the first time in 1851 (Rowell 1997). The 
Latin word lupus means wolf and erythema is defined as redness of the skin occurring with 
skin injury, infection or inflammation. Another symbol commonly used in the context of the 
disease is a butterfly. These words are apt in describing the disorder in which patients may 
have gnawed facial injuries resembling a wolf bite or a butterfly-shaped rash extending over 
the face. The term lupus appeared in medical literature over 1000 years ago (Rowell 1997). 
An early description of the discoid form of cutaneous lupus dates back to 1833, although the 
word discoid was not coined until 40 years later and eventually the concept was refined 
according to the distribution and extent of the skin changes in 1934 (Rowell 1997). 
Apparently the first delineation of subacute cutaneous disease was already published at the 
end of 19th century (Rowell 1997), even though the case report by Richard D Sontheimer in 
1979 (Sontheimer et  al. 1979) is generally considered a fundamental description. Some 
patients, however, have fever, anaemia and pain around joints in conjunction with cutaneous 
manifestations, and these symptoms were named as systemic in 1875. By the early part of the 
next century systemic lupus had become recognised, while the discovery of autoantibodies 
and antinuclear antigens in 1950-1960’s (Meller et al. 2005) improved the understanding of 
the disease with autoimmunity in nature and high variability. 
 
3 Classification and nomenclature of lupus erythematosus 
Lupus erythematosus (LE) is a heterogeneous autoimmune disease associated with aberrant 
immune responses including production of autoantibodies and immune complexes. Clinical 
presentations of the disease range from mainly skin-confined manifestations to a progressive 
multisystem disease with involvement of internal organs, such as kidney, lung, heart and 




genes, gender and environmental triggering factors, making the identification of these pieces a 
challenging task.  
 
3.1 Cutaneous lupus erythematosus 
Nomenclature for the cutaneous manifestations of LE-related skin disease was initially 
proposed by James N Gilliam in 1977 (Sontheimer 1997). This classification scheme divides 
all skin lesions into LE-specific and LE-nonspecific skin disease (Table 1). LE-specific skin 
disease  includes  the  classic  subtypes  of  cutaneous  lupus  erythematosus  (CLE)  with  distinct  
histopathological features: chronic cutaneous lupus erythematosus, of which discoid lupus 
erythematosus (DLE) is the most common form, subacute cutaneous lupus erythematosus 
(SCLE) and acute cutaneous lupus erythematosus (ACLE). Histologically nonspecific LE 
lesions are associated with LE, but are not specific to the disease process itself. That is to say, 
identical lesions can also be encountered in other disease processes. Nonspecific skin lesions, 
such as vasculitis, livedo reticularis and alopecia are seen in patients with CLE (Tebbe 2004); 
in SLE these lesions are more frequent and reflect disease activity (Werth 2005).  
 
Gilliam meant his nomenclature to be a logical classification system for the extremely varied 
skin changes rather than a rigid scheme to define subsets of LE (Sontheimer 1997). The 
nebulous usage of terminology over the years has resulted in several attempts to provide new 
sets of criteria, however, with no satisfactory approach being addressed (Sontheimer 1997). 
 
 
Table 1. The Gilliam classification of skin lesions associated with LE 
(modified after Lin et al. 2007). 
LE-specific skin disease LE-nonspecific skin disease 
Chronic cutaneous LE 
1. Classic discoid LE 
a. Localised DLE 
b. Generalised DLE 




Subacute cutaneous LE 
1. Annular SCLE 
2. Papulosquamous/psoriasiform 
Calcinotis cutis 
LE-nonspecific bullous lesions 
Urticaria 
Acute cutaneous LE 
1. Localised (malar rash; butterfly rash) 
2. Generalised acute cutaneous LE (SLE rash) 
Papulonodular mucinosis 
Cutis laxa/anetoderma 
Acanthosis nigricans  
 Erythema multiforme 
 Leg ulcers 






3.2 Systemic lupus erythematosus 
The classification of systemic lupus erythematosus (SLE), which is a multisystem disease 
characterised by the production of several autoantibodies, is based on the criteria established 
by the American College of Rheumatology (ACR) (Hochberg 1997; Tan et al. 1982). The 
fulfilment of four out of 11 clinical and laboratory criteria (Table 2) is sufficient for 
verification of SLE. The current criteria have been criticised for emphasising skin too much in 
the identification of a multiorgan disease (Albrecht et al. 2004). Four dermatologic features 
are included, namely butterfly rash, discoid lupus, photosensitivity and oral ulcers. 
Consequently, individuals presenting with only the aforementioned skin manifestations can be 
classified as having SLE. On the other hand, a maximum of 20% of DLE and up to 50% of 
SCLE patients have four or more positive ACR criteria (Kuhn and Sontheimer 2008; 
Sontheimer 2005). Thus it is evident that the ACR criteria characterise a heterogeneous group 
of patients and are less useful for exclusion of SLE in patients with predominant cutaneous 
manifestations (Kuhn and Sontheimer 2008). Reevaluation and recommendations have been 
made and suggest that the revised criteria should include Ro/SSA and La/SSB autoantibody 
testing, skin biopsy and control groups representing relevant differential diagnoses in 
sufficient numbers to assess specific diagnostic problems (Albrecht et al. 2004). 
 
 
Table 2. The American College of Rheumatology Criteria for the 
classification of SLE (modified from Wakeland et al. 2001). 
Category Symptom 




Systemic criteria Arthritis 
Serositis (pleuritis or pericarditis) 
Proteinuria 
Neurological disorders (seizures or psychosis)  
Laboratory criteria Haematologic: 
Haemolytic anaemia, leukopaenia, lymphopaenia or 
thrombocytopaenia  
Immunologic: 
Antibodies against dsDNA, Sm and phospholipids, such 
as cardiolipin 






The diagnosis of different subtypes of LE is based on clinical and histopathological features 
in combination with laboratory abnormalities and immunogenetic patterns specific for, but not 
limited to, a subtype. Skin biopsy showing LE-specific histology is needed to confirm the 
diagnosis (Werth 2005), but is less useful in determining the clinical subtype (Walling and 
Sontheimer 2009). Assessment of the autoantibody profile is helpful in contributing to the 
presence of SLE, but has a more limited role in the diagnosis of CLE (Walling and 
Sontheimer 2009). Signs and symptoms evolve over time and therefore, it may take several 
years before the proper diagnosis is made; for SLE an average of four years is spent before a 
correct diagnosis is reached (Manzi 2009). On the other hand, SLE is often over-diagnosed. 
Only about half of the individuals with presumptive diagnosis by a nonrheumatologist could 
be confirmed as having SLE (Narain et al. 2004). 
 
As skin disease is the second most frequent clinical manifestation of SLE (Lin et  al. 2007; 
Werth 2005), all patients presenting with cutaneous findings should be comprehensively 
evaluated for possible systemic involvement at baseline (Walling and Sontheimer 2009). In 
addition, certain patterns of systemic disease activity can be seen in cutaneous forms of LE. 
Therefore,  it  is  important  to  carefully  follow  up  these  patients  to  assure  that  SLE  does  not  
develop. For instance, patients with SCLE are reported to have mild systemic illness marked 
with musculoskeletal complaints and serological abnormalities at the time of cutaneous 
outbreak (Sontheimer 2005). Severe central nervous system or renal defects are rare. 
Approximately one third of DLE patients have extracutaneous signs of the disease (Kuhn and 
Sontheimer 2008). It has been estimated that 5% of patients with localised and 20% with 
generalised DLE lesions develop SLE, whereas about 10-15% of SCLE cases progress to an 
overt systemic disease (Lee and Sinha 2006; Sontheimer 2005). Variables important for 
disease progression to SLE include signs of nephropathy, arthralgias and elevated antinuclear 
antibody (ANA) titres ( 1:320) (Tebbe et al. 1997). It has been suggested that high levels of 
Ro/SSA  autoantibodies  in  SCLE  patients  may  serve  as  a  prognostic  tool  to  predict  
development of systemic inflammatory disease (Popovic et al. 2007a).  
 
CLE is not a life-threatening illness and has an excellent prognosis. Nevertheless, scarring 
lesions can be socially debilitating and patients often experience reduced quality of life (see 
section 7). Lethal outcome seems to be a rare event; in a 10 year follow-up 10% of the SCLE 
patients died, but only one from LE complications (Tebbe and Orfanos 1997). The survival of 
patients with SLE has improved markedly over the past 50 years, and today up to 90% of 
patients survive at least ten years after diagnosis of SLE (Manzi 2009). Unfortunately, 
prognosis of SLE remains considerably poorer in many developing countries (Borchers et al. 
2009).  Despite  better  outcome,  patients  are  now  facing  a  greater  risk  of  diseases  related  to  
ageing, such as cardiovascular disease, cancer and osteoporosis (Manzi 2009). Among 
patients with SLE, the incidence ratio for cancer is 1.2; the risk of myocardial infarction is six 






4 Clinical and histopathological features 
 
4.1 Discoid lupus erythematosus 
Women are affected at the 2-3:1 ratio with a typical onset age of 30 years. A rash is usually 
the sole manifestation of DLE and well-demarcated, erythematous, scarring plaques, being the 
most common skin involvement, are seen in the head and neck region, although palms and 
soles can be affected as well. (Crowson and Magro 2001). Lesions on the head and neck 
region are referred to as localised whereas those occurring both above and below the neck are 
called generalised DLE (Lee and Sinha 2006). Occasional patients with disseminated lesions 
will manifest haematological and other abnormalities indicative of supervening SLE. Skin 
without lesions rarely contains deposits of immunoglobulins that are seen as a band-like 
structure in biopsy specimens obtained from patients with DLE (see section 4.4). (Crowson 
and Magro 2001). 
 
4.2 Subacute cutaneous lupus erythematosus 
The disease incidence is 3-4 times higher in women than in men and patients are typically in 
their 20s and 30s (Lee and Sinha 2006). Patients present with papulosquamous, psoriasiform 
and/or annular-polycyclic skin eruption on the upper trunk and experience enhanced 
photosentivity (Crowson and Magro 2001). SCLE lesions typically resolve without scarring. 
Approximately one fifth of patients have been reported to develop typical DLE or ACLE 
lesions during their disease course. (Sontheimer 2005). Affected individuals may also have a 
wide range of other LE-specific (such as mouth ulcers) or LE-nonspecific (such as vitiligo-
like lesions and nonscarring alopecia) skin manifestations (Crowson and Magro 2001). High 
titres of Ro/SSA autoantibodies against extractable nuclear antigens (ENA) are frequently 
displayed in the sera obtained from patients (Sontheimer 2005). SCLE may be induced by a 
variety of medications, such as antihypertensive drugs, especially calcium channel blockers 
(Sontheimer et al. 2009; Srivastava et al. 2003). 
 
4.3 Acute cutaneous and systemic lupus erythematosus 
The peak of onset is around 30 years of age, although manifestations may appear at any time 
point from early to mid adulthood. There is a female predominance: nine out of ten affected 
individuals are women. Articular, that is, joint-related defects are common at the outset, but 
ultimately 80% of the SLE patients will have cutaneous manifestations during the course of 
their disease (Crowson and Magro 2001). A localised malar, butterfly-shaped rash over the 
face and bridge of the nose is most commonly seen and may occur concurrently with other 
symptoms of lupus or precede systemic illness by months to years (Lee and Sinha 2006). 
ACLE typically  presents  abruptly  in  the  context  of  systemic  disease;  the  clinical  activity  of  
the lesions cycles in parallel with the activity of underlying SLE (Lee and Sinha 2006; 
Rothfield et al. 2006). The appearance of generalised lesions in the form of erythema of the 
face, upper trunk or extremities is usually related to sun exposure, to which ACLE is 




with exacerbation of systemic manifestations (Kuhn and Sontheimer 2008). Over 70% of 
ACLE  patients  meet  the  ACR  criteria  for  SLE  that  is  utilised  for  verifying  the  diagnosis  
together with vesicles and bullae arising on sun-exposed skin (Werth 2005). Virtually all 
patients with ACLE eventually progress to overt SLE (Lee and Sinha 2006). Although the 
different  forms  of  CLE  are  usually  thought  of  as  distinct  entities  of  LE,  any  of  their  
dermatological changes can occur in patients with SLE (Yell et al. 1996). A minority of 
patients (15-20%) have skin involvement resembling that of DLE and lesions mimicking the 
annular shape seen in SCLE are found in a few patients (10-15%) positive for Ro/SSA 
autoantibodies. ACLE lesions are typically seen in 30-50% of SLE patients.  
 
4.4 Characteristic histopathology 
Typical histopathological skin changes include interface dermatitis accompanied by 
lymphocytic infiltrate which is most prominent in DLE; hyperkeratosis; epidermal atrophy, 
i.e. thinning of the epithelium especially in SCLE; vacuolisation of the basal epidermis is 
often seen in SLE; epidermal basement membrane thickening; and melanin pigment 
incontinence (Crowson and Magro 2001; Rothfield et al. 2006). Varying combinations of 
these features are seen in CLE and SLE. Conventional histopathology is reinforced with 
immunopathological lupus band testing that is often referred to as DIF, direct 
immunofluorescence testing. The lupus band is defined as deposits of immunoglobulins and 
complement proteins along the dermal-epidermal junction of lesional skin biopsy specimens. 
More than 60% of patients with CLE have proteins in their lesional skin. Therefore, positive 
test result supports the diagnosis of LE, but a negative finding does not rule out a diagnosis of 
lupus. (Rothfield et al. 2006). 
 
5 Laboratory findings 
 
5.1 Haematological features 
Systemic disease is accompanied with various haematological abnormalities that are rarely 
seen in CLE (Wallace et al. 1992). These include anaemia, leukopaenia, lymphopaenia and 
thrombocytopaenia. In other words, patients have insufficient haemoglobin levels and reduced 
numbers of red blood cells, leukocytes, lymphocytes and platelets. In addition, sedimentation 
rate, a measure of inflammation and immune activation, is elevated in almost all patients and 
falls to normal levels during the inactive phase of the disease. Serum complement (C) levels, 
the most important being C3 and C4, are also depressed. (Rothfield et al. 2006). 
 
5.2 Autoantibodies 
SLE is virtually always accompanied by the production of autoantibodies of multiple 
specificities (Arbuckle et al. 2003), which are infrequent in DLE (Wallace et al. 1992). Some 
autoantibodies may contribute directly to the pathogenic changes of SLE (Arbuckle et al. 




many years and their appearance tends to follow a predictable course (Arbuckle et al. 2003). 
Virtually all patients with SLE have a positive ANA test (Rothfield et al. 2006). However, 
ANAs are by no means specific for SLE; they can be detected in 25-80% of patients with 
CLE (Tebbe 2004) and sporadically in 2% of the female population over the age of 40 
(Wakeland et  al. 2001). Instead, antibodies against double-stranded deoxyribonucleic acid 
(dsDNA), Smith (Sm) antigens and ribonucleoprotein (RNP) are fairly specific for SLE, while 
less common in CLE (Chlebus et al. 1998; Rothfield et al. 2006; Sontheimer 2005). Ro/SSA 
autoantibodies are considered characteristic for SCLE, occurring in approximately 70% of 
patients (Sontheimer 2005). These autoantibodies are seen in SLE with similar frequency than 
in SCLE (Chlebus et al. 1998), whereas the majority of DLE patients are negative for Ro 
autoantibodies (Lee et al. 1994; Popovic et al. 2007a). A minority of the healthy population 
presents with Ro autoantibodies as well, implicating nonspecificity for LE (McCauliffe 1997). 
Subjects positive for Ro tend to have cutaneous manifestations and photosensitivity not 
necessarily associated with LE or Sjögren’s syndrome (SS) (McCauliffe 1997). Follow-up 
studies have shown that Ro-positive patients with diverse clinical presentation at baseline 
have a dynamic disease process with skin disease progression and development of new 
autoimmune diseases (Popovic et al. 2008; Simmons-O'Brien et al. 1995). The typical clinical 
and histopathological features as well as laboratory findings of DLE, SCLE and SLE are 
summarised in Table 3. 
 
 
Table 3. Characteristic clinical, histopathological, haematological and immunological 
features for DLE, SCLE and SLE. 
 DLE SCLE ACLE/SLE 
Age at diagnosis 30 y 20-30 y 30 y 
Female to male ratio 2-4:1 3-5:1 9:1 

















Positive lupus band test 
on lesional skin 
90% 60% >90% 




Kidney, lung, heart, 
central nervous system 
Haematological changes + ++ +++ 













6 Other clinical manifestations 
Besides the affected skin, general symptoms, such as fever and fatigue, are present in a high 
proportion of SLE patients. Fatigue can be seen during periods of disease activity and is 
associated with pain, insomnia and depression (Walling and Sontheimer 2009). More than 
80% of patients have low grade or spiking fever at the time of diagnosis (Rothfield et al. 
2006). Furthermore, patients with SLE suffer from extensive visceral involvement (Rothfield 
et al. 2006). This includes cardiovascular manifestations and renal disease as well as central 
nervous system involvement in forms of severe headaches, seizures and organic brain 
damage. Depression and anxiety are common psychological problems. Fever, headache, 
cardiovascular disease and arthritis/arthralgias are most often recorded for patients with CLE, 
while renal involment is virtually absent (Chlebus et al. 1998; Popovic et al. 2007b; Wallace 
et al. 1992). Symptoms of the nervous system tend to be much milder in patients with SCLE 
than in SLE (Walling and Sontheimer 2009). Other autoimmune diseases, such as SS, may be 
present in both SCLE and SLE (Rothfield et al. 2006; Sontheimer 2005); the prevalence of SS 
is 43% in SCLE (Black et al. 2002) and 20% in SLE (Ramos-Casals et al. 2007). 
 
7 Quality of life 
The  physical,  psychological  as  well  as  economic  burden  of  the  disease  is  especially  
devastating because young adults are often affected. As a potentially disabling disease 
persisting over decades and not infrequently associated with vocational handicap and 
unemployment, LE may lead to limited quality of life (Meller et al. 2005). The effects of skin 
disease on patients’ lives are measured with the self-administrated Skindex questionnaire that 
consists of 29 items related to daily performance, emotions and symptoms on a 5-point 
response scale (Chren et  al. 1997). Patients with widespread DLE experienced the greatest 
worsening of life quality (mean Skindex score=93.6), the impact being somewhat smaller in 
SCLE (79.4), ACLE (76.3) and localised DLE (74.2) (Moghadam-Kia et al. 2009). The mean 
CLASI damage score was also highest among subjects with DLE (mean score=10.2). These 
results are not surprising as DLE lesions typically produce marked facial scarring and 
dyspigmentation as they resolve and nearly 45% of DLE patients have a vocational handicap 
(Moghadam-Kia et al. 2009). Furthermore, CLE is considered to be the third most common 
cause of industrial disability from dermatological diseases (Tebbe and Orfanos 1997).  
 
8 Treatment for cutaneous lupus erythematosus 
General treatment for CLE includes photoprotective strategies: avoidance of sunlight, 
artificial sources of UV exposure and photosensitising drugs, as well as use of broad spectrum 
sunscreens (Kuhn et al. 2005). Smoking cessation should be encouraged, as evidence 
indicates that smoking interferes with the efficacy of antimalarial therapy and exacerbates 
disease activity (Walling and Sontheimer 2009). Because of their favourable safety profile, 
topical therapies, such as corticosteroids and calcineurin inhibitors are most often employed 
(Sontheimer 2005; Walling and Sontheimer 2009). Widespread skin manifestations are 
treated with oral antimalarial drugs (chloroquine, hydroxychloroquine) (Kuhn et al. 2005). 




or thalidomide are arguably the most efficacious (Kuhn et  al. 2005; Rothfield et al. 2006; 
Walling and Sontheimer 2009). Recombinant tumour necrosis factor (TNF)-  inhibiting 
agents may turn out to be a successful biologic therapy. However, their ability to induce 
dermatological changes dampens promising views (Rothfield et al. 2006; Walling and 
Sontheimer 2009). 
 
9 Prevalence and incidence 
Prevalence and incidence are used as estimates of how common a condition is within a 
population at a given time. Prevalence is defined as the total number of cases, and incidence 
as the number of new cases within a time frame, usually a year (Danchenko et al. 2006). 
Although population-based studies assessing the prevalence of CLE are still lacking, it is 
estimated to be two to three-fold more prevalent than SLE (Tebbe and Orfanos 1997) and 
prevalence is dependent on the population studied (Lin et al. 2007). The prevalence of SLE in 
Finland is 28/100,000 (Helve 1985). Worldwide SLE rates show considerable disparities, 
prevalence being the lowest in Northern Ireland (25/100,000) and the UK (26/100,000) and 
the highest in Spain (91/100,000). Incidence was found to be the lowest in Iceland 
(3/100,000) and Japan (3/100,000) and the highest in the USA (5/100,000) and France 
(5/100,000). This high variability may result from methodological differences of studies or 
reflect true differences across populations. (Danchenko et al. 2006).  
 
At rheumatology practice, one CLE case for every seven cases of SLE has been reported 
(Wallace et al. 1992). Fresh figures from the USA show a prevalence of 73/100,000 and an 
incidence of 4/100,000 for CLE (Durosaro et  al. 2009). One population-based study 
suggested a prevalence of 28/100,000 for DLE, while the incidence (2/100,000) was 
estimated to be quite similar for DLE and SLE (reviewed in Lin et al. 2007). More recently a 
Swedish study estimated that the prevalence of Ro/SSA-positive SCLE is 6-14/100,000 and 
incidence is 0.7/100,000 (Popovic et  al. 2007b). Furthermore, some ethnic differences in 
prevalence have been reported: SCLE is uncommon in African-Americans, Koreans and 
Chinese, while DLE is more prevalent in African-Americans than Caucasians (Sontheimer 
2005). SLE is far less common in Europeans and their descendants compared to other 
ethnicities (Borchers et al. 2009). 
 
10 Aetiology 
The aetiology of LE is not still fully understood, but multiple factors such as genetic 
predisposition, environmental exposure and hormonal factors contribute (Criswell 2008). 
Autoimmunity develops in many cases over years by a process that combines immune 
activation, genetic susceptibility and environmental factors in a certain individual at a certain 
time point (Nancy and Yehuda 2009). Based on this, a tentative model has been proposed 
(Rhodes and Vyse 2007; Rhodes and Vyse 2008; Wandstrat and Wakeland 2001). In this 
scenario, individuals have a genetic predisposition (see sections 14.1 and 14.2) to disease 
according to the number of susceptibility alleles they carry; genetic susceptibility, on the other 




adulthood imply that a number of triggers occurring together or sequentially over a limited 
period  of  time  are  required  for  the  disease  to  develop,  which  happens  when  a  threshold  of  
genetic and environmental susceptibility effects is reached. For those with little genetic risk, 
disease may never develop despite strong or prolonged exposure to the relevant 
environmental triggers.  
 
10.1 The female gender 
In general, women are more prone than men to develop autoimmune diseases. The female 
preponderance is not seen only in LE, but also in SS (approximately 90% of patients are 
women), RA (>70%) and multiple sclerosis (>65%) (Invernizzi et al. 2009). Estimations on 
the  female  to  male  ratio  vary  in  CLE (2-3:1),  but  it  seems that  the  female  predominance  is  
much less pronounced than in SLE (9:1) (Tebbe and Orfanos 1997; Vera-Recabarren et al. 
2009b). A large cohort study from the 1970s reported equal numbers of women and men with 
DLE (Lin et al. 2007), while more recent studies observed a female to male ratio of  4:1 for 
DLE (Moghadam-Kia et al. 2009) and that of 3-5:1 for SCLE (Moghadam-Kia et al. 2009; 
Popovic et al. 2007a). Reported gender differences in disease severity and manifestations are 
few. According to one study that investigated 205 female and 103 male patients with CLE, 
affected women had a higher prevalence of clinical and immunological abnormalities (Vera-
Recabarren et al. 2009b). For instance, women had more often arthralgias (29%) and elevated 
ANA titres (46%) compared to men (12% and 17%, respectively). Though less common in 
men, when it does occur, SLE tends to run a more severe course (Yacoub Wasef 2004).  
 
The reasons for the gender bias in autoimmune diseases remain elusive, although sex 
hormones may play a role. Female hormones promote humoral immune responses and 
lymphocyte self-reactivity (Ackerman 2006). An alternative theory is related to the gene-dose 
effect of genes located on the X chromosome (Invernizzi et al. 2009) and epigenetic 
mechanisms regarding altered methylation patterns of genes in the inactive X chromosome in 
women (Hewagama and Richardson 2009). The risk of SLE in men with Klinefelter’s 
syndrome (47, XXY) is predicted to be 14 times higher compared with normal men (46, XY) 
(Scofield et al. 2008). In addition, the SLE candidate gene MEC2P that regulates methylation 
is located on the X chromosome (Rhodes and Vyse 2008; Suarez-Gestal et al. 2009). The role 
of sex hormones in disease pathogenesis is undeniable, but a more complex interplay of 
hormones and epigenetic mechanisms, like methylation, cannot be excluded. 
 
10.2 Environmental triggering factors 
The nature of environmental triggers predisposing to LE is partly unknown, but some of them 
may already operate early in life (Edwards and Cooper 2006). Irrespective of the 
environmental  exposure,  it  is  most  likely  a  common  factor  of  low  penetrance,  as  otherwise  
there would be a dramatic increase of cases among individuals with the relevant exposure. 
One might also hypothesise that it is unlikely to be a single common factor because LE is not 
a highly prevalent disease. (Rhodes and Vyse 2008). Numerous environmental factors are 




smoking, medications, infectious agents, chemicals and diet  (Nancy and Yehuda 2009; Sarzi-
Puttini et al. 2005; Shapiro et al. 2004). Common to these aforementioned precipitants is that 
they induce apoptosis, autoantigen translocation to cell surface and other inflammatory events 
known to trigger LE (Shapiro et al. 2004). 
 
10.2.1 Smoking 
Several studies have consistently showed an association between cigarette smoking and CLE 
(Boeckler et al. 2009; Gallego et al. 1999; Lipsker et al. 2006; Miot et al. 2005) and reported 
up to a ten-fold excess risk for the development of DLE (Gallego et al. 1999; Miot et  al. 
2005). Notably, most of the refractory cases not responding to treatment were currently 
smoking female DLE patients (Moghadam-Kia et al. 2009). Current, rather than past, 
smoking may be a hazard for the development of SLE (Costenbader et al. 2004), but the 
relationship is somewhat controversial (Costenbader and Karlson 2005) and the immunologic 
subphenotype of an individual appears to play a role (Freemer et al. 2006). Smoking is 
significantly associated with numerous adverse cutaneous consequences (Freiman et al. 
2004). In addition, tobacco smoke contains toxic components that have multiple biological 
effects from tissue damage to immune system modulation (Costenbader and Karlson 2006; 
Nancy and Yehuda 2009). However, little is known about the exact pathological mechanisms 
involved (Boeckler et al. 2009). The challenge will be to convince patients to cease smoking 
since it clearly poses increased risk and, on some occasions, cessation of smoking has resulted 
in complete remission of LE (Lipsker et  al. 2006; Miot et al. 2005). Meanwhile, the 
underlying mechanism and gene-environment interactions in genetically prone individuals 
deserve to be studied in more detail. 
 
10.3 Ultraviolet light 
Exposure to UV light is one of the major factors known to trigger cutaneous disease activity. 
Sunlight can precipitate disease de novo or aggravate existing disease. Summertime exposure 
to UV light may lead to systemic flares three to six months later (Lin et al. 2007). The 
different wavelengths of UV spectrum, namely UVA and UVB have varying biological 
effects on the skin (Angotti 2004; Lin et al. 2007). UVB does not penetrate deeper than the 
epidermal layer and is strongly absorbed by DNA, while UVA penetrates deeper into the 
dermis (Angotti 2004). Potential molecular targets include DNA, ribonucleic acid (RNA), 
proteins and lipids (Angotti 2004; Lin et al. 2007). UVB has significant photobiological 
effects including induction of apoptosis through DNA damage; translocation of nuclear 
autoantigens to the surface of keratinocytes, thereby stimulating an autoimmune response; 
generation of novel antigenic products; and dermal vessel activation (Angotti 2004; Kuhn and 
Bijl 2008). Cutaneous inflammation is further promoted by UVB-induced release of 
proinflammatory cytokines, such as interleukin (IL)-10 and TNF- , which in turn induce 
adhesion molecule and chemokine expression to facilitate inflammatory cell, as well as 
interferon-producing cell, recruitment into the skin (Angotti 2004; Lin et al. 2007). 
Consequently, more effector cytokines are released, thus amplifying chemokine production 





Three  of  the  11  ACR  classification  criteria,  namely  malar  rash,  discoid  LE  and  
photosensitivity, relate to photodistribution, suggesting an important role of UV light in the 
pathogenesis (Lin et al. 2007). Sensitivity to light in forms of prolonged and delayed 
erythema is a common feature in all patients with cutaneous or systemic disease (Lehmann 
and Homey 2009). The strong association between photosensitivity and LE has led to the 
assumption that abnormal photoreactivity is pivotal for the pathogenesis of cutaneous and 
systemic  variants  of  the  disease  (Kuhn et al. 2005). However, the ACR definition of 
photosensitivity is extremely vague and fulfilled when patient or treating physician reports an 
adverse reaction to sunlight, and may encompass a number of related dermatoses, such as 
polymorphous light eruption (Lin et  al. 2007). Malar rash is often indistinguishable from 
photosensitivity and these two criteria were criticised as not being independent in the 
classification of SLE (Albrecht et  al. 2004). A detailed clinical history of patients including 
morphology and distribution of the rash, its duration and relation to sun exposure is vital for 
the diagnosis and assessment of photosensitivity, although negative history does not 
necessarily rule out sensitivity to sun light (Kuhn and Bijl 2008). For some patients it might 
be difficult to link the worsening of their disease to the detrimental effects of sunlight because 
of the latency period of up to several weeks in the development of skin lesions (Lehmann and 
Homey 2009). Therefore, a standardised photoprovocation test performed at different 
wavelengths has been developed to evaluate photosensitivity (Lehmann and Homey 2009), as 
both single and repeated exposures to UV radiation provoke skin lesions in patients (Angotti 
2004). Pathologic skin reactions are most pronounced in SCLE followed by DLE and SLE 
(Lehmann et al. 1990). Not all patients, however, show positive reaction after phototesting 
despite their history of photosensitivity (Lehmann and Homey 2009), which may be due to 
delayed lesion formation, interindividual variation, methodological differences and bias in 
patient selection (Kuhn and Bijl 2008; Lehmann and Homey 2009). A practical consequence 
of  photosensitivity  is  that  patients  are  not  adequately  protected  by  window  glass  or  by  
conventional sunscreens (Kuhn and Sontheimer 2008). 
 
10.4 Apoptosis 
A direct effect of sun exposure is the induction of apoptosis in suprabasal keratinocytes 
(Angotti 2004). Programmed cell death or apoptosis is a normal biological process 
characterised by cell shrinkage, nuclear condensation, cytoplasmic contraction and the 
packaging of cellular components within membranes before their budding from the apoptotic 
cells as apoptotic bodies. UV light has the capability to induce apoptosis in keratinocytes with 
different mechanisms, but the complex molecular machinery controlling keratinocyte 
apoptosis in the epidermis is still poorly known (Angotti 2004). In normal physiological 
conditions, apoptotic keratinocytes are eliminated quickly to prevent the release of harmful 
intracellular constituents and their exposure to the immune system (Bijl and Kallenberg 
2006). In CLE skin, expression of apoptosis blocking protein, Bcl-2, is diminished, and 
accordingly, the number of apoptotic keratinocytes is increased (Baima and Sticherling 2001; 




upregulation of p53 (Chung et al. 1998; Pablos et al. 1999) by UV-induced DNA damage 
and/or TNF-  (Lin et al. 2007). Therefore, the increased rate of apoptosis could be mediated 
directly by UV light or be a consequence of UV-induced cytokine mechanisms (Angotti 
2004). It was further demonstrated that apoptotic cells tend to accumulate in the skin of 
patients after UV radiation possibly as a result of impaired or delayed clearance (Kuhn et al. 
2006). Unremoved cells may release proinflammatory compounds and potential autoantigens, 
and consequently provoke tissue inflammation and an autoimmune response. A similar 
increase in apoptosis rate, clearance defects and consecutive accumulation of apoptotic cells 
has been reported to occur also in SLE (Baumann et al. 2002; Emlen et al. 1994; Gaipl et al. 
2006; Lorenz et  al. 2002). Impaired clearance by phagocytosis may be partly genetically 
determined  (Mok and  Lau  2003).  A novel  theory  anticipates  a  role  for  Ro52 autoantibodies  
which are upregulated in CLE keratinocytes in response to UV light (Oke et  al. 2009) and 
known to associate with induction of apoptosis (Espinosa et  al. 2006) as well as impaired 
phagocytosis (Reefman et al. 2007).  
 
11 Pathogenesis 
The pathogenesis of CLE is not completely understood, but it is thought that development of 
the skin disease is related to the same autoimmune abnormalities responsible for the systemic 
disease (Rothfield et  al. 2006). Although there is a link between skin and systemic 
manifestations, often skin may flare up independently or patients may have SLE without skin 
disease (Werth 2007). Treatments also may improve the skin without an effect on systemic 
disease suggesting that there are pathogenic differences. The immune dysfunction seems to be 
more important for SLE (Mok and Lau 2003), while exogenous agent(s) leading to skin 
inflammation may be central in CLE (Lee and Sinha 2006; Lin et al. 2007).  
 
11.1 Pathogenesis of cutaneous lupus erythematosus 
As basal keratinocytes are the primary focus of injury seen in CLE, skin may be the site of 
autoimmune initiation. It has become evident that UV radiation exposure significantly 
compromises the immune system and immunosuppressive effects are manifold (Kuhn et al. 
2005). A potential pathogenic model where UV is the key player was first proposed by Norris 
(1993) (Figure 1). In this model exposure to UV light induces apoptosis of keratinocytes and 
the release of proinflammatory cytokines (reviewed in Kuhn and Bijl 2008). The presence or 
even accumulation of apoptotic cells results in the induction of inflammatory skin lesions. 
Emerging new evidence adds enhanced type 1 interferon (IFN) production into the CLE 
pathogenesis (Wenzel and Tuting 2007; Wenzel and Tuting 2008; Wenzel et al. 2009). Based 
on this model, several factors are required concurrently for CLE to develop, namely abnormal 
reactivity to UV light, the presence of antibodies and the presence of activated lymphocytes 
(Lin et al. 2007). The autoimmune response in skin can be viewed in three phases: initiation, 






In the initiation phase, UV exposure is responsible for enhanced keratinocyte apoptosis and 
translocation of autoantigens, such as Ro/SSA and DNA, to the cell surface, resulting in 
increased autoantigen display to the immune system. Genetically determined malfunctions in 
apoptosis or clearance system may further accumulate antigenic load. This setting, coupled 
with a UV-induced proinflammatory cytokine release,  is  a proper environment for the break 
























Figure 1. The three phases of CLE pathogenesis. UV light stimulates cell surface expression of Ro/SSA 
autoantigens and keratinocyte apoptosis. The release of adhesion molecules leads to migration of lymphocytes 
and plasmacytoid dendritic cells (pDC) that produce more effector cytokines amplifying chemokine production 
and cell recruitment. Circulating Ro antibodies bind to keratinocytes, cytotoxic lymphocytes infiltrate the dermis 
and destroy basal keratinocytes. IFN, interferon. 
 
 
Amplification of the immune response is orchestrated by cytokines that induce local mediators 
of inflammation, including adhesion molecules, selectins and chemokines. Adhesion molecule 
expression may account for the increased homing of lymphocytes to the skin and the 
keratinocyte targets. (Lee and Sinha 2006). Mediator molecules also recruit and activate 
dendritic cells that release type 1 IFNs (Lin et  al. 2007), which together with the cellular 
attack on keratinocytes, may promote further cytokine release to perpetuate and amplify the 





Deposition of immune complexes in tissues and subsequent autoantibody response are 
supposed to cause target damage (Lee and Sinha 2006). Another mechanistic explanation is 
antibody-dependent cellular cytotoxity, in which circulating Ro/SSA autoantibodies bind to 
keratinocytes expressing surface Ro autoantigen, thereby facilitating infiltration of cytotoxic 
lymphocytes and destruction of basal keratinocytes (Lee and Sinha 2006; Lin et al. 2007).  
 
11.2 Pathogenesis of systemic lupus erythematosus 
Production of harmful autoantibodies is the primary immunological disturbance and cause of 
tissue injury in SLE. A plausible disease model has been suggested (Mok and Lau 2003), and 
has been recently refined by placing the susceptibility genes in the pathogenetic context 
(Rhodes and Vyse 2008). Many factors are thought to be involved in the production of 
autoantibodies: defective immune regulation, such as errant clearance of apoptotic cells and 
immune complexes; dysregulation of T- and B-cells resulting in loss of self-tolerance; as well 
as cytokine milieu imbalance (Mok and Lau 2003). All these phenomena, in turn, are a 
consequence of multiple genes, precipitating environmental factors and gender effects. 
Several of the identified genes predisposing to SLE have functions related to these pathways 
(see section 14.2.1 and Figure 3). 
 
11.3 Type 1 interferons 
Type 1 IFNs are a family of cytokines produced by plasmacytoid dendritic cells (pDC) 
(Ronnblom and Pascual 2008). They bind to common receptor complexes and initiate a 
signalling cascade leading to the transcription of IFN-inducible genes (Kyogoku and Tsuchiya 
2007). Patients with SLE have an increased espression of type 1 IFN regulated genes because 
of continuous production of IFN-  (Ronnblom and Pascual 2008). A similar upregulation of 
IFN-induced  genes  has  also  been  demonstrated  in  the  skin  and  blood  of  patients  with  DLE 
(Lee and Sinha 2006). IFN-  is important in the maturation of dendritic cells and the 
production of proinflammatory cytokines, and has diverse immunomodulatory effects, 
including stimulation of the T helper cell (Th) 1 pathway, promotion of B-cell activation and 
control of apoptosis (Ronnblom and Pascual 2008). Furthermore, elevated serum IFN-  levels 
in patients with SLE correlate with disease activity and severity. In SLE, a type 1 IFN driven 
disease model has been proposed in which unabated activation of pDCs sustains constitutive 
IFN-  production and further activation of autoreactive T- and B-cells (Kyogoku and 
Tsuchiya 2007; Ronnblom and Pascual 2008). Studies on genes in this pathway have 
identified IRF5, TYK2 and STAT4 as risk genes in SLE susceptibility (Remmers et al. 2007; 
Sigurdsson et al. 2005).  
 
11.3.1 Type 1 interferons in cutaneous lupus erythematosus 
It has become evident that the type 1 IFN system plays an important role in the development 
of CLE skin lesions (Wenzel and Tuting 2007; Wenzel and Tuting 2008; Wenzel et al. 2009). 
Patients with CLE are found to have large numbers of pDCs in their skin lesions (Wenzel and 




reflected the characteristic distribution of the inflammatory infiltrate seen in CLE (Wenzel et 
al. 2007) and that expression was upregulated in patients with acute widespread lesions 
(Wenzel et al. 2005). It has been suggested that production of type 1 IFNs induces Th1-biased 
inflammation through induction of IFN-inducible chemokines leading to the recruitment of 
chemokine receptor expressing T-cells into skin lesions (Wenzel et al. 2005). That the IFN-
induced proteins and chemokines are expressed on the same areas where cytotoxic 
lymphocytes invade the basal dermis and cause keratinocyte death and that peripheral 
lymphocytes expressing the chemokine receptor are decreased in numbers support the cellular 
immune response theory (Wenzel et  al. 2005; Wenzel and Tuting 2008). Lesional induction 
of type 1 IFNs appears to be a hallmark of skin inflammation, but the primary stimulus is still 
unclear. It has been proposed that the accumulation of apoptotic cells in CLE skin and 
subsequent release of proinflammatory compounds may trigger skin lesions (Wenzel and 
Tuting 2008). The chronic inflammation may be further amplified by self-perpetuating 
mechanisms (Wenzel and Tuting 2007).  
 
12 Genetic mapping in complex diseases 
Completion of the human genome sequence in 2001 (Lander et al. 2001; Venter et al. 2001), 
launching the International HapMap Project (International HapMap Consortium 2003; 
International HapMap Consortium et al. 2007; http://www.hapmap.org) in 2002, an attempt to 
catalogue all variation in the human genome by the 1000 Genomes Project 
(http://www.1000genomes.org), development of elegant high-throughput genotyping 
techniques and massive publicly available databases of genetic information have all opened 
new doors to map genetic variants underlying complex diseases, such as LE. Genetic mapping 
of complex diseases, denoted as localisation of genetic factors underlying phenotypes on the 
basis of correlation with DNA variation, has turned out to be a challenging task based on a 
number of reasons. Complex diseases are not inherited in a straightforward Mendelian, 
monogenic fashion (Criswell 2008). This implies that there are multiple common genetic 
factors (f>5%) for the disease, each of which has modest increments in risk (i.e. odds ratios 
(OR) are usually 1.1-1.5), and explains only a small fraction of heritability (Altshuler et  al. 
2008). The missing heritability or “dark inheritance” not identified by current genome-wide 
strategies is thought be composed of low-frequency (0.5-5%) variants that increase disease 
risk two to three-fold and could contribute substantially to unexplained heritability, and rare 
variants (f<0.5%) of small effect (Manolio et al. 2009). Inherited genotype does not always 
correspond to resultant phenotype due to incomplete penetrance of predisposing loci or 
disease may develop in the absence of apparent genetic risk factors. Not all affected 
individuals for a particular disease share the same genetic risk (genetic heterogeneity), and 
finally, there remains an important role for interacting environmental factors (see section 
14.4) (Criswell 2008).  
 
Complex  diseases  may  be  relatively  common  in  a  given  population.  In  general,  they  often  
have a late onset, hence having little or no impact on reproductive fitness, which allows 
causative alleles to rise to moderate frequency in the population. It is also believed that some 




susceptibility to diseases because of changes in living conditions accompanying civilisation. 
Disease-causing alleles could be maintained at high frequency when the disease burden is 
counterbalanced by a beneficial phenotype. In accordance with this, the “common disease-
common variant” hypothesis was postulated, which suggests that common polymorphisms 
having a minor allele frequency (MAF) over 1% might contribute to susceptibility to common 
diseases (reviewed in Altshuler et al. 2008).  This  does  not  necessarily  mean  that  all  causal  
mutations are common, only that some common variants exist and could be used to pinpoint 
loci for detailed study. 
 
Before 2006 the standard principle to identify susceptibility genes was either through 
positional mapping approaches or by functional candidate gene studies. Positional mapping 
approaches are hypothesis-free and consist of two steps: initial linkage studies in families 
with multiple affected individuals provide information on both the position and genetic effect 
of underlying disease loci, while association mapping extends linkage analysis to map the 
position of a disease gene to a much higher resolution (Todd 2001; Wang et  al. 2003). The 
candidate gene method aims to identify candidate genes based on prior knowledge of the 
disease pathogenesis, functions of the selected genes, and in some cases, data on animal 
models  of  the  disease  (Wang et al. 2003). Utilising these two methods, MAMDC1 and 
GIMAP5 genes, respectively, were identified as disease-causing genes in Finnish SLE 
families (Hellquist et al. 2007; Hellquist et al. 2009). 
 
In general, genetic linkage and association analysis rely on similar principles, that is, 
coinheritance of adjacent DNA variants. Linkage identifies alleles or haplotypes (i.e. stretches 
of alleles) that are inherited intact over several generations in families; association relies on 
the retention of adjacent DNA variants close to disease causing mutation over many 
generations (Cardon and Bell 2001). Thus, association studies can be regarded as very large 
linkage studies of unobserved, hypothetical pedigrees. Following the introduction of high-
throughput genotyping technology it is possible today to genotype a million single nucleotide 
polymorphisms (SNP) in one individual at a time, which has led genetic research into the 
genome-wide association study (GWAS) era. The GWA analysis combines the power and 
resolution of a traditional association study with the hypothesis-free methodology of a 
conventional genome-wide linkage scan. In 2006, eight GWASs were published, the number 
of which had grown to 536 by September, 2009 (Hindorff et al. 2010; 
http://www.genome.gov/gwastudies), and GWAS is now the most widely used approach for 
genetic mapping (McCarthy et al. 2008). 
 
12.1 Association analysis  
Association analysis is more powerful than a linkage study to detect genetic contributions to 
complex diseases (Risch and Merikangas 1996) and is based on the comparison of differences 
in allele frequencies between cases and appropriate controls. The control individuals can 
either be unrelated, matched individuals or unaffected family members. Contrary to linkage 
analysis that focuses on recent recombination events, association looks for historical 




Bell 2001). The most common strategy for gene identification by association is the case-
control study design (McCarthy et al. 2008). The advantage of a case-control study is that 
sporadic patients are obtained more easily than families and that this method is a powerful 
strategy  for  identifying  genes  of  small  effects  that  contribute  to  complex  traits  (Cardon and  
Bell 2001; Risch 2000). Despite its ease, association strategy has encountered many 
limitations, including lack of reproducibility of results, insufficient sample size, poor study 
design, poorly matched controls and unaccurate recording of phenotypic information (Cardon 
and Bell 2001). The problem of spurious associations is explained by population stratification, 
meaning that individuals with different ancestral and demographic histories, and therefore 
different allele frequencies independent of the disease, are present in the population (Cardon 
and Bell 2001; McCarthy et al. 2008). To overcome the problem of population stratification, 
various  approaches  have  been  developed  that  use  controls  selected  from  the  families  of  
affected individuals. Basically, these methods use the parental alleles or haplotypes that are 
not transmitted to affected offspring as the control sample (Borecki and Province 2008). The 
most popular approach to account for stratification is the transmission disequilibrium test 
(Spielman et al. 1993). 
 
12.2 The genome-wide association study approach 
The  GWAS  approach  is  based  on  association  but  does  not  rely  on  any  prior  hypothesis  
regarding position or function and aims to capture a substantial proportion of common 
variation in the human genome by using knowledge of linkage disequilibrium (LD) 
relationships. The publication of GWAS of 14,000 cases and 3,000 controls by Wellcome 
Trust Case Control Consortium (2007) can be considered as a fundamental step into the GWA 
era  and  this  approach  is  now  routinely  used  in  genetic  research  of  complex  diseases.  Even  
though GWASs have been very successful in identifying susceptibility genes, there are still 
limitations. First, GWASs generally identify only common genetic variants and the studies 
performed thus far have had good power to detect alleles that are common in the general 
population and have modest effect sizes (Altshuler et  al. 2008).  Thus  rare  variants  or  those  
with small effect sizes are likely to have been missed in current GWAS designs. Second, the 
coverage of GWASs is nonrandom, meaning that subsets of genomic regions are poorly 
covered (Frazer et al. 2009). Third, in most cases the association signals identified in GWASs 
are likely to be indirect associations due to LD and not the causal variants themselves 
(Altshuler et al. 2008). Finally, GWASs have been criticised for focusing on populations of 
European ancestry and using other ancestries only for limited replication thus making the risk 
assessment in other populations problematic (Frazer et  al. 2009). This addresses the 
importance of recruiting populations of different ethnicity for primary genotyping and the 







13 Genetic variation in the human genome 
Genetic variations in the human genome can be either common or rare but obviously with a 
continuous  distribution.  Common variants  are  defined  as  genetic  variants  with  a  MAF of  at  
least one percent in the population and are considered synonymous with polymorphisms. Rare 
variants occurring at less than one percent of frequency are generally defined as mutations. 
(Frazer et al. 2009). Genetic variation includes SNPs and simple sequence repeats, such as 
micro- and minisatellites, as well as structural variants, namely insertion-deletions (indels), 
block substitutions, inversions, copy number variants, segmental duplications and 
translocations (Feuk et al. 2006; Frazer et al. 2009) (Figure 2). The vast majority of genetic 
variants are hypothesised to be neutral, in other words, they do not contribute to phenotypic 
variation. However, the relative percentage of neutral and nonneutral variants awaits to be 
determined (Frazer et al. 2009). The spontaneous mutation rate of SNPs is estimated to be as 
low as 2.5x10-8 mutations per base and generation (Nachman and Crowell 2000) whereas 
genomic rearrangements, such as copy number variants, appear to be two to four orders of 
magnitude more prevalent (Lupski 2007). 
 
13.1 Single nucleotide polymorphisms 
The most abundant small-scale variation in the human genome is a SNP. They are base 
substitutions in which a single nucleotide is altered into another at a fixed position of the 
sequence (Figure 2). The number of SNPs within the human genome is approximately 11 
million, meaning that there is one base substitution for every 300 nucleotides (Feuk et  al. 
2006; Frazer et al. 2009). It has been estimated that approximately 2% of the SNPs are 
biologically important (Orr and Chanock 2008). Nonsynonymous SNPs are located in the 
protein coding region of the gene and cause amino acid substitutions, frame shifts or 
termination of protein translation. Synonymous SNPs within exons do not alter protein 
primary structure, but can affect messenger RNA (mRNA) stability or alter splicing signals. 
SNPs outside the protein coding regions can also be of functional importance, either by their 
location  on  promoter  regions  where  they  may  interfere  with  gene  regulation  by  altering  







Figure 2. Classes of human genetic variation. DNA sequence variations affecting a single nucleotide are known 
as single nucleotide polymorphisms. Insertion-deletion variants occur when base pairs are present in some 
genomes but absent in others. Simple sequence repeats are short tandem repeat units, block substitutions are a 
string of adjacent nucleotides that varies between two genomes, while in an inversion variant the order of the 
base pairs is reversed in a defined section of a chromosome. Copy number variants occur when identical or 
nearly identical sequences are repeated in some chromosomes, while segmental duplications are repeated 
segments with near-identical sequence. Translocations are rearrangements of chromosomal sections between 









14 Genetics of lupus erythematosus 
Burch and Rowell (1968) have hypothesised that the polygenic predisposition for the 
development of DLE is different from that of SLE: “When a genuine transition from DLE to 
SLE occurs, the affected patient is genetically predisposed to both diseases” (reviewed in Lee 
and Sinha 2006). The question of whether the genetic susceptibility to cutaneous or systemic 
disease is overlapping or distinct remains yet unsolved. Based on the evidence available to 
date, it is plausible that differential expression of multiple genes together with an array of 
environmental exposures leads to differential clinical expression of disease phenotypes. While 
the genetics of SLE has been extensively studied over the decades, the genetic architecture of 
CLE remains to be elucidated. 
 
A strong genetic component underlies SLE and a similar genetic basis of inheritance likely 
holds true for CLE as well. SLE exhibits familial clustering with a sibling risk ratio ( s) as 
high as 29 (Alarcon-Segovia et al. 2005); in other words siblings of an affected individual are 
29 times more likely to develop SLE than those without an affected sibling. Familial 
clustering has also been documented for DLE; the prevalence of DLE was 3.5% in 255 first 
degree relatives of patients compared to that of 0.5% in control families (Lawrence et al. 
1987). Higher concordance rates between monozygotic twins with SLE (>35%) relative to 
dizygotic twins and other full siblings (2-5%) (Deapen et  al. 1992) also support important 
roles for genes. The prevalence of CLE is too low for a formal concordance study with twin 
pairs (Millard and McGregor 2001). However, occurrence of DLE in monozygotic twins has 
been described in a few case reports (Steagall et al. 1962; Wojnarowska 1983 and refrences 
therein). The genetic component is marked by heritability estimates of 66% and 44% for SLE 
and DLE, respectively (Lawrence et al. 1987). 
 
14.1 Susceptibility genes for cutaneous lupus erythematosus 
A genetic predisposition is probably the greatest risk factor for CLE despite the multitude of 
environmental exposures. There are only a few confirmed risk loci in CLE, including human 
leukocyte antigen (HLA) genes, the TNF-  promoter and complement factors (Lee and Sinha 
2006; Millard and McGregor 2001; Osmola et  al. 2004). Many genetic regions outside the 
HLA locus appear to be involved in susceptibility to CLE or demonstrate association or 
linkage with the Ro/SSA autoantibody response. These include loci encoding cytokines and 
their receptors, adhesion molecules, antioxidant enzymes and apoptosis genes (Millard and 
McGregor 2001; Osmola et al. 2004) (Table 4). In addition, the non-HLA complement gene 
C1QA and DNA exonuclease TREX1 have been implicated in CLE susceptibility (Racila et al. 
2003; Rice et al. 2007). Many of these (HLA genes, complement components, IL-10, Fc  
receptor II, C1QA and TREX1) have been linked to SLE as well, supporting the theory of 
overlapping pathogenesis (Lee and Sinha 2006; Lee-Kirsch et al. 2007; Martens et al. 2009). 
Unfortunately, studies on CLE have been difficult to evaluate and replicate due to insufficient 
sample sizes and because risk estimates are seldom reported. Some of the CLE susceptibility 





14.1.1 Insights into CLE susceptibility genes 
The extremely diverse HLA region on chromosome 6p21.3 plays a vital role in the immune 
system. Historically, the HLA region has been subdivided into three classes that encode not 
only  the  HLA  but  also  complement  and  TNF  molecules.  Several  studies  in  SCLE  have  
identified a common HLA susceptibility haplotype (HLA-A1, B8, DR3, DQ2) particularly in 
the presence of Ro/SSA autoantibodies (Sontheimer 2005). Relatively few studies conducted 
in DLE implicate an association with HLA (HLA-A1, B8, DR3 and B7, DR2 haplotypes), 
while others have not found such a relationship (Lee and Sinha 2006; Millard and McGregor 
2001; Osmola et al. 2004). The mechanism by which HLA genes influence disease are not 
fully understood, but are likely to be related to their role in T-cell repertoire selection, antigen 
presentation and immune activation (Lee and Sinha 2006). 
 
 
Table 4. Genes outside the HLA region suggested as being involved with CLE pathogenesis 
(modified after Millard and McGregor 2001; Osmola et al. 2004). 







Cytokine receptors FCGR2, 









Antioxidant enzymes GSTM1 1p13 Ro/SSA production 






Non-HLA complement C1QA 1p36.3-p34.1 SCLE phenotype 
C1QA, complement component 1, q subcomponent, A chain; FCGR2,  Fc  fragment  of  IgG,  low  affinity  IIa,  
receptor (CD32); GSTM1, glutathione S-transferase mu 1; ICAM-1, intercellular adhesion molecule 1; 
IL, interleukin; TCR, T-cell receptor; TREX1, three prime repair exonuclease 1 
1 Millard and McGregor (2001) and references therein; Racila et al. (2003); Rice et al. (2007) 
 
 
Inherited deficiencies of C2 and C4 molecules have been strongly linked to DLE, SCLE and 
Ro/SSA response (Lee and Sinha 2006; Millard and McGregor 2001; Osmola et al. 2004). 
Proposed basis for these associations include a failure to clear immune complexes and 
apoptotic cells, but also a false positive relationship due to strong linkage disquilibrium (LD) 
(Millard and McGregor 2001; Osmola et al. 2004). SCLE patients homozygous for the C1QA 
gene variant (C1qA-Gly70GGA) have lower serum levels of C1q protein compared to patients 
not carrying this variant (Racila et al. 2003). It is not known how the genetic variation results 
in functional abnormality and is related to pathogenesis, but defects in apoptotic clearance or 





Keratinocytes expressing the rare (f=15% in healthy population) TNF-  promoter 
polymorphism (-308A) exhibit greatly enhanced TNF-  production in response to UV light 
(Millard and McGregor 2001) and a strong association to photosensitive SCLE has been 
demonstrated (Werth et  al. 2000). Interestingly, risk of developing DLE and prevalence of 
discoid lesions in SLE have been reported to be higher in subjects that produce low levels of 
TNF-  (Suarez et al. 2005). The pathogenic mechanism probably acts through translocation 
of antigens to cell surface and their exposure to the immune system (Werth et  al. 2000). 
However, the independent role of TNF-  has been disputed due to the strong LD across the 
HLA region that makes identification of causal alleles difficult (Fernando et al. 2007; Millard 
et al. 2001).  
 
Several studies have shown involvement of intercellular adhesion molecule 1 (ICAM-1) in the 
pathogenesis of various skin diseases, including different forms of CLE (Kuhn et al. 2002). 
Increased keratinocyte expression of ICAM-1 has been demonstrated in evolving UV-induced 
lesions  in  CLE,  but  not  in  healthy  controls  (Kuhn et al. 2002; Nyberg et  al. 1999). Strong 
keratinocyte  expression  of  ICAM-1  was  already  found  one  week  after  photoprovocation  
suggesting that these early changes reflect an underlying defect in the mechanisms that 
regulate adhesion molecule expression in LE (Nyberg et al. 1999). Sera obtained from SCLE 
patients display elevated levels of soluble ICAM-1 (Nyberg et al. 1997). Thus ICAM-1 itself 
or its upstream regulators are putative disease candidate genes. A recently identified new SLE 
susceptibility gene ITGAM is  a  receptor  for  ICAM-1 (Harley et  al. 2008; Hom et  al. 2008; 
Nath et al. 2008). Despite the supporting evidence, a candidate gene analysis of three 
photosensitive disorders failed to demonstrate association to ICAM-1 (Millard and McGregor 
2001), possibly due to a small number of samples leading to insufficient power. 
 
The family of glutathione-S-transferase (GST) enzymes is involved in detoxification of 
hazardous foreign compounds (Hayes and Strange 2000). A number of genetic 
polymorphisms altering enzyme activity have been described at the four major GST loci, 
namely GSTA, GSTM, GSTP and GSTT. The GSTP1 variant (I105V) has a protective effect in 
CLE patients with polymorphous light eruption (Millard et al. 2008), while homozygosity of 
GSTM1 null  alleles  is  associated  with  Ro/SSA  autoantibody  production  in  SLE  patients  
(Ollier et al. 1996). Interestingly, GSTs have shown to interact with environmental exposures 
in SLE (Fraser et al. 2003; Karlson et  al. 2007). Moreover, GST polymorphisms seem to 
account for the level of chromosomal damage, formation of DNA adducts and tobacco 
consumption in individuals who smoke (Jourenkova et al. 1998; Piipari et al. 2003; Tuimala 
et al. 2004). 
 
14.2 Susceptibility genes for systemic lupus erythematosus 
The  genetics  of  SLE  has  been  studied  since  the  early  1970s  when  the  first  HLA allele 
association was found (Harley et al. 2006). The following four decades have been witness to a 
tremendous genetic technological revolution facilitating the identification of susceptibility 
loci and genes for complex diseases, including SLE. When this doctoral study was started in 




score >3.2) for significant linkage (Harley et  al. 2006). Four years later in 2010, there are 
more than 30 known disease contributing genes of which over half have been discovered in 
the past three years underscoring the success of new genetic mapping approaches (Moser et 
al. 2009). 
 
The linkage regions established and independently confirmed by genome-wide scans include 
1q23, 1q31-32, 1q41-41, 2q37, 4p16, 6p21-p12, 11p13, 12q24, 16q12-13 (reviewed in Harley 
et al. 2006; Rhodes and Vyse 2007). Linkage on chromosomes 5p15-5q11 and 14q21-q23 had 
been implicated (Gaffney et al. 1998; Koskenmies et al. 2004; Lindqvist et al. 2000; Namjou 
et al. 2002a; Shai et al. 1999), but the disease contributing gene MAMDC1 on chromosome 
14 had not been identified until recently (Hellquist et al. 2009). Two meta-analyses have 
further identified two significantly linked regions, namely 20p11-q13.13 (Forabosco et al. 
2006) and 16p12-16q13 (Lee and Nath 2005). A subsequent fine-mapping of the 16p12-
16q13 region recently identified association to the integrin alpha M (ITGAM)  gene,  also  
known as CD11b or complement receptor 3, which is expressed primarily on neutrophils, 
macrophages and dendritic cells and can bind a variety of ligands, including ICAM-1 (Hom et 
al. 2008; Nath et al. 2008). Simultaneously, this gene was shown to be strongly associated to 
SLE in two of the GWAS (Harley et al. 2008; Hom et al. 2008) and its robust role has been 
confirmed thereafter in several studies encompassing different populations (Han et al. 2009b; 
Molineros et al. 2009; Yang et al. 2009). 
 
Before the introduction of GWASs there were nine established susceptibility genes identified 
through candidate gene studies or linkage approach (Moser et al. 2009), including HLA locus, 
complement locus, TNF- , Fc RIIA and Fc RIIIA, PDCD1, PTPN22, IRF5, STAT4 and 
TREX1. Other genes, such as TYK2 and CTLA4, requiring further work have either low levels 
of significance attached to them or the existing results are inconsistent (Rhodes and Vyse 
2008). Applying the hypothesis-free whole genome strategies to the hunt for SLE genes has 
considerably broadened our understanding of the genetic basis and biochemical pathways of 
this disease. At the beginning of 2008, three high-density GWASs (Graham et al. 2008; 
Harley et al. 2008; Hom et  al. 2008) and one smaller study (Kozyrev et al. 2008) were 
published. Together, the studies have evaluated more than 5,000 patients, a number that had 
only been a wild dream a couple of years before. One additional GWAS in Han Chinese (Han 
et al. 2009a), two replication studies (Gateva et al. 2009; Suarez-Gestal et al. 2009) and one 
meta-analysis (Graham et al. 2009) have caused the number of convincing genetic 
associations to swell to well over 30. The vast majority of the susceptibility genes fall into 
key biological pathways shown to be important in the disease pathogenesis, including 
immune complex clearance, immune signal transduction and interferon pathways, but there is 
also a group of genes without any apparent immunological role or assigned function (Figure 
3). Not all of the newly described findings, however, have attained high levels of 
confirmation and further work is required to clearly establish their effects and key 
polymorphisms (Rhodes and Vyse 2008). Presenting all identified genes is beyond the scope 
of this literature review. However, some of the genes placed in the context of disease 
pathways are discussed below, while a more comprehensive picture is given in recent review 





Figure 3. Immune function pathways that contain established candidate genes involved in systemic lupus erythematosus. Genes involved in each pathway are indicated. TLR, 




14.2.1 Insights into SLE susceptibility genes 
Interferon regulatory factor 5 (IRF5)  and tyrosine kinase 2 (TYK2)  are both members of the 
IFN-Toll like receptor signalling pathway together with STAT4 and TNFAIP3.  After  the  
identification of IRF5 and TYK2 in SLE susceptibility (Sigurdsson et al. 2005), IRF5 has 
sparked a flurry of confirmation and characterisation reports not only in SLE but also in other 
diseases, namely rheumatoid arthritis (RA), inflammatory bowel disease, SS and multiple 
sclerosis (Dideberg et al. 2007; Kristjansdottir et al. 2008; Miceli-Richard et  al. 2007; 
Sigurdsson et al. 2007). In contrast, TYK2 has remained a somewhat controversial finding 
(Graham et al. 2007; Harley et  al. 2008). The IRF5 gene encodes a transcription factor 
involved in the control of inflammatory and immune responses. Thus, genetic variants 
altering the actions of IRF5 could result in a prolonged proinflammatory response in 
genetically susceptible individuals (Rhodes and Vyse 2008). Four functional polymorphisms 
have been described: rs200460 creating a donor splice site (Graham et al. 2006); rs10954213 
altering polyadenylation signal and transcript stability (Cunninghame Graham et al. 2007); 30 
bp indel likely to influence transcription initiation of target genes (Graham et al. 2007; Moser 
et al. 2009); and finally 5 bp CGGGG indel upstream of the first untranslated exon creating 
an additional SP1 binding site (Sigurdsson et al. 2008a). It has been claimed that this latter 
polymorphism explains the association signal arising from multiple SNPs in the IRF5 gene 
and a general role in autoimmune disorders has been suggested (Sigurdsson et  al. 2008a).  
TYK2 is an intracellular signalling molecule that interacts with the IFN-  receptor (Rhodes 
and Vyse 2007). No functional data exist for the detected polymorphisms in TYK2, but their 
location implicates altered protein function or missplicing events (Graham et al. 2007; 
Sigurdsson et al. 2005). Deficiency of TYK2 leads to defects of multiple cytokine pathways, 
including type 1 IFN, IL-6, -10, -12 and -23 and to an accelerated humoral immune response 
(Minegishi et al. 2006).  
 
Signal transducer and activator of transcription 4 (STAT4) was simultaneously demonstrated 
in  RA  and  SLE  (Remmers et al. 2007)  and has been confirmed thereafter by independent 
replication studies (Abelson et al. 2009; Sigurdsson et al. 2008b; Taylor et al. 2008), also in 
the Finnish SLE family cohort (Hellquist et al. 2009)  and in SS (Korman et al. 2008). 
Furthermore, common polymorphisms of STAT4 predispose to more severe disease 
manifestations (Hellquist et  al. 2009; Sigurdsson et al. 2008b; Taylor et al. 2008). Studies 
also demonstrate that STAT4 acts by an additive manner with IRF5 (Abelson et  al. 2009; 
Nordmark et al. 2009; Sigurdsson et al. 2008b). STAT4 encodes a transcription factor that is 
induced by cytokines, including type 1 IFNs, IL-6 and IL-23. After activation it promotes 
differentiation  of  IFN-  producing  Th1  cells,  and  possibly  that  of  Th17  cells  (Rhodes  and  
Vyse 2008), which play a role in a wide range of autoimmune diseases (Pernis 2009). 
 
Tumour necrosis factor- -induced protein 3 (TNFAIP3) was discovered and replicated in two 
sequential studies (Graham et  al. 2008; Musone et al. 2008). TNFAIP3 encodes an enzyme 
required for the downstream signal transduction of Toll-like receptors and is a negative 
regulator of nuclear factor- B pathway, thus playing a key role in modulating a broad range 




al. 2008). Preliminary functional experiments demonstrate that SLE risk is associated with 
reduced inhibition of nuclear factor- B activity (Musone et al. 2008). 
 
Identification of three genes, namely BANK1, BLK and LYN (Harley et al. 2008; Hom et al. 
2008; Kozyrev et  al. 2008), involved in B-cell signalling attested the importance of this 
pathway in SLE pathobiology. B-cell scaffold protein with ankyrin repeats 1 (BANK1) is a B-
cell adapter protein expressed predominantly on B-cells and is thought to sustain B-cell 
activity, thus increasing disease risk (Kozyrev et al. 2008). LYN is a protein tyrosine kinase 
that physically associates the B-cell receptor with is binding partner BANK1, while BLK 
affects functions associated with the development of B-cells before the appearance of the B-
cell receptor (BCR) (Moser et al. 2009). All these genes play a critical role in controlling the 
activation of B-cells following signalling through BCR (Rhodes and Vyse 2008). After ligand 
binding and BCR aggregation, an early intracellular event is the recruitment and activation of 
SCR family protein tyrosine kinases, including BLK and LYN, which mediate further 
intracellular signalling. BANK1 acts downstream of LYN, thus facilitating release of 
intracellular calcium, which is an important event in B-cell activation. Cytotoxic T-
lymphocyte-associated protein 4 (CTLA4) belongs functionally to the same category of 
lymphocyte signalling with BANK1, BLK and LYN. It is a member of the immunoglobulin 
family of receptors that downregulates activated T-cells (Rhodes and Vyse 2008). CTLA4 
association to SLE has mainly relied on meta-analysis (Barreto et  al. 2004; Lee et al. 2005) 
and its independent role has been less confident until recently (Graham et al. 2006). 
Interestingly, the association pattern appears to be disease-specific in different autoimmune 
diseases (Graham et al. 2006; Zhernakova et al. 2005).  
 
14.3 Shared genetic predisposing factors in autoimmune diseases 
Extensive concomitance of autoimmune disease has been reported in some patients and 
families (Zhernakova et al. 2009). This clustering may be explained by a common set of 
general susceptibility genes shared among family members, while disease-specific genes and 
environmental factors may dictate the final disease phenotype (Rhodes and Vyse 2007; Wong 
and Tsao 2006). The HLA region  is  a  classical  example  of  shared  genetic  basis  of  
autoimmunity. Linkage scans already revealed considerable overlap in chromosomal location 
of linkage regions between multiple autoimmune diseases (Wandstrat and Wakeland 2001) 
and common genes were pinpointed, including CTLA4, PDCD1, PTPN22 and 
NOD2/CARD15 in type 1 diabetes, RA and SLE (Rioux and Abbas 2005). GWASs have 
thereafter brought to light several candidate genes many of which are shared between 
different autoimmune diseases and tend to cluster around the same immunological pathways 
(Lettre and Rioux 2008; Zhernakova et al. 2009). Examples include STAT4 in RA and SLE; 
and TNFAIP3 in RA, celiac disease and SLE. Clustering of the genes suggest shared 
underlying causal mechanism and further our understanding of the development and 
concomitance of these diseases. The lack of genetic overlap, on the other hand, suggests 





14.4 Gene-gene and gene-environment interactions 
Gene-gene interaction, or epistasis, is a phenomenon that occurs when the effect of one locus 
is altered by the effect of another locus, that is, the effect of carrying more than one variant is 
different than would be expected by simply combining the effects of each individual variant 
(Cordell 2002; Hirschhorn and Daly 2005). Genetic interaction of distinct genes may result in 
multiple disease pathways with a variety of disease phenotypes that vary in severity (Wong 
and Tsao 2006). Consequently, diseases are of different intensities between individuals and in 
different ethnicities. From the mathematical point of view, epistasis is defined as deviation 
from additivity in a linear model (Moore and Williams 2009). Hence, statistical interaction 
does not necessarily imply interaction on the biological level and thus may not easily translate 
into physical interaction between proteins (Cordell 2002; Moore and Williams 2005). 
Furthermore, standard employment of linear models in genetic epidemiology challenges the 
identification of gene-gene interactions because these models have limited ability to detect 
nonlinear patterns of interaction (Moore and Williams 2009).  
 
Disease development and course may be further influenced by interacting genes and 
environmental exposures. One example of such interactions in LE is UV light leading to an 
increased load of apoptotic material in an individual with genetically less efficient clearance 
mechanisms (Jonsen et al. 2007). GST polymorphisms have shown to interact with 
environmental exposures, resulting in increased risk and earlier diagnosis of SLE (Fraser et 
al. 2003; Karlson et  al. 2007). N-acetyl transferase gene, in combination with chemical 
exposure, may also increase susceptibility to SLE (Jonsen et al. 2007). Identification of these 
interactions might be beneficial in disease prevention and treatment targeting. In order to 
effectively study gene-environment interactions several problems are to be overcome: time 
frame of environmental influence is protracted; exposure(s) can already take place in utero 
and may also interact with each other temporally; and large study cohorts with representative 
controls are needed (Jonsen et al. 2007). Retrospective studies are prone to recall bias 
whereas prospective studies are more accurate, but time-consuming (Costenbader and Karlson 
2006). Finally, epigenetic mechanisms (i.e. chromatin changes that alter gene expression 
without affecting DNA sequence) possibly being targets of environmental factors may 
mediate the interaction between genes and environment (Jonsen et al. 2007). 
 
15 Matrix metalloproteinases 
Matrix metalloproteinases (MMP) constitute a large family of 24 zinc-dependent 
multifunctional, proteolytic enzymes that degrade extracellular matrix and basement 
membrane components (Overall and Lopez-Otin 2002). They also play a role in several 
pivotal cellular processes, including cellular growth, apoptosis, tissue repair, angiogenesis, 
inflammation and immunity (Parks et al. 2004). MMPs are divided into six subgroups 
according to their structure and substrate preference, namely collagenases (MMP-1, -8, -13), 
gelatinases (MMP-2, -9), stromelysins (MMP-13, -10), matrilysins (MMP-7, -26), membrane-
type MMPs (MMP-14, -15, -16, -17, -24, -25) and other MMPs (MMP-19, -20, -21, -27, -28) 




gene expression, pericellular localisation, as well as enzyme activation and inactivation (Parks 
et al. 2004). Typically these proteins are not expressed in normal healthy tissues, by contrast, 
expression is detected in diseased or inflamed tissues (Parks et al. 2004). Under normal 
physiological conditions, extracellular matrix remodelling occurs in a precisely controlled 
manner, whereas during the course of the disease in part in an attempt at repair, but is 
frequently dysregulated and destructive. MMP activity is blocked by general inhibitors, such 
as 2-macroglobulin, or specifically by tissue inhibitors of metalloproteinases (TIMP). There 
are four endogenous human TIMPs identified, including TIMP-1, -2, -3 and 4, which block 
MMP function by binding to the catalytic sites. Results indicate that TIMP-3 is a major 
regulator of metalloproteinases in vivo. In addition to MMP inhibition, TIMPs are involved in 
a broad range of other biological activities, such as apoptosis. Lack of efficacy and untoward 
side effects still constrain other exogenous approaches to inhibit metalloproteinase activity. 
(Murphy and Nagase 2008).  
 
15.1 Matrix metalloproteinases in lupus erythematosus 
Specific MMPs have been implicated in the aetiology of SLE, but their exact role in 
cutaneous disease is as yet unknown. One small-scale study has been conducted in which 
expression of MMP-3 was absent in the regions of basal layer destruction in DLE specimens, 
suggesting that MMP-3 may be involved in the pathogenesis of interface dermatitis (Gunduz 
et al. 2006). MMP-9 was diffused throughout the entire epidermis and was also detected in 
inflammatory infiltrate cells. Experimental evidence demonstrates a wide range of functions 
for both MMP-9 and MMP-3 in LE disease progress. MMP-9 protein activity is increased in 
the  sera  and  plasma of  SLE patients  (Chang et  al. 2008; Faber-Elmann et al. 2002). It may 
serve as a potential biomarker in neuropsychiatric SLE (Efthimiou and Blanco 2009), since 
high intrathecal and serum levels of MMP-9 have been detected in diseased individuals 
(Ainiala et al. 2004; Trysberg et al. 2004). Upregulation of this protein may also be 
responsible for the vascular damage seen in SLE peripheral neuropathy (Mawrin et al. 2003). 
It has also been documented that MMP-9 levels inversely correlate with dsDNA 
autoantibodies in affected individuals (Jiang et al. 2009; Makowski and Ramsby 2003). 
Interestingly, cultured peripheral blood mononuclear cells from SLE patients experiencing 
remission (amelioration) of their disease secrete more MMP-9 than cells obtained from 
relapsed (exacerbated) patients (Matache et  al. 2003).  In  pregnant  SLE  women  the  disease  
may worsen in 60% of the cases. However, low levels of MMP-9 activity similar to those of 
control individuals were observed in patients (Munoz-Valle et al. 2003). Individuals affected 
with SLE have increased serum plasma levels of MMP-3 not correlating with disease activity 
(Zucker et al. 1999). Upregulation of the MMP-3 protein may contribute to vessel wall 
damage in SLE neuropathy (Mawrin et al. 2003), and increased serum levels of MMP-3, as 
well as MMP-9, may play a role in the pathogenesis of SLE nephritis (Jiang et  al. 2009; 
Kotajima et al. 1998). Sera samples obtained from SLE patients display MMP-19, which may 
have a role in arthritis-associated tissue destruction (Sedlacek et  al. 1998). Serum levels of 
TIMP-1  are  reported  to  be  comparable  or  even  lower  in  SLE  patients  compared  to  healthy  
controls (Jiang et  al. 2009; Matache et  al. 2003; Robak et al. 2006). Decreased TIMP-1 




tissues (Mandel et al. 2004) and detected serum imbalance between MMP-9 and its main 
inhibitor TIMP-1 may contribute to the pathogenesis of lupus nephritis (Jiang et  al. 2009). 
Taken together, these results suggest that MMPs, as well as TIMPs, may have important and 
multiple roles in the progression of inflammation and tissue damage in various rheumatic 
diseases including LE (Mandel et al. 2004). 
 
15.2 Matrix metalloproteinases in apoptosis 
Some MMPs function in apoptosis either directly or indirectly regulating survival signals 
generated by specific adhesive events. Actions can be both apoptotic (MMPs-1, -2, -3, -7, -9, 
-11) and antiapoptotic (MMPs-2, -3, -7, -9, -11). Proteolysis leads to enhancement or 
attenuation of apoptosis in a context dependent manner, in which the proteolytic cascade and 
cell fate is influenced by concentrations, tissue specificity and balance between MMPs and 
TIMPs. (Mannello et  al. 2005). In terms of LE, MMP-7 mediates the release of the Fas 
ligand, a well known death factor, implicated in controlling mesangial inflammation in lupus 
nephritis (Tsukinoki et al. 2004). Endothelial cell apoptosis and survival of epithelial cells is 
influenced by MMP-14 (Langlois et al. 2005; Nagavarapu et al. 2002). Furthermore, TIMP-3 





AIMS OF THE STUDY 
 
The broad aim of this study was to identify genetic variants conferring susceptibility to CLE, 
and investigate whether genetic susceptibility is shared between clinically different 
conditions, that is, cutaneous and systemic variants of LE. The specific aims of the study 
were: 
 
1. To epidemiologically characterise different subtypes of LE in order to better 
understand their clinical manifestations, typical laboratory aberrations, systemic 
symptoms, disease associations and triggering factors (I). 
 
2. To  test  whether  SLE  candidate  genes  that  were  published  prior  to  this  study  would  
constitute a risk in Finnish patients, and whether their combinations show evidence of 
epistasis, i.e. gene-gene interaction (II, III). In addition, the tissue expression of 
proteins encoded by the best associating genes was determined (II). 
 
3. To evaluate the role of ITGAM in CLE (IV), and screen other GWAS-identified SLE 
susceptibility genes for their association to CLE (unpublished results).  
 
4. To perform subphenotype analyses to study the correlation between relevant clinical 
variables and genotypes (II, III, IV). 
 
5. To study the function and expression of certain MMPs and their specific inhibitors, 
TIMPs, in the skin lesions of CLE patients. Especially MMPs known to regulate 




MATERIALS AND METHODS 
 
1 Study subjects and tissue samples 
 
1.1 Ethical considerations 
This study was based on large sample collections representing Finnish and Swedish patients 
with their respective control individuals. All participants gave written informed consent for 
participation in genetic studies and the study protocols were reviewed and approved by the 
Ethical Review Boards of Helsinki and Tampere University Central Hospitals, Finland, and 
the Regional Human Ethics Committee at the Karolinska University Hospital, the Institutional 
Ethics Board and the Regional Ethics Board, Sweden. All studies were conducted according 
to the Declaration of Helsinki ethical principles for medical research involving human 
subjects. The number of independent cases and control individuals from each population and 
the number of families are described in detail below and their clinical characteristics are 
summarised in Tables 5 and 6. 
 
1.2 Finnish case-control cohort (Studies I-IV) 
The  Finnish  case-control  cohort  consists  of  177  DLE,  42  SCLE,  91  SLE  (85  with  DNA  
sample available) cases and 356 control individuals, and has been the basis for the genetic 
studies in this thesis. All patients with a clinical diagnosis of lupus attending the Departments 
of Dermatology of Helsinki or Tampere University Central Hospitals during 1995-2005 were 
identified from corresponding hospital registries and contacted by mail or phone. Patients 
visiting these hospitals for routine lupus controls in 2005-2006 were also asked to participate. 
The presence of LE-specific skin manifestations diagnosed by a dermatologist at some point 
of the disease course was a prerequisite for inclusion in the study. Correct diagnosis was 
verified  from  the  patients’  hospital  records.  The  diagnosis  of  DLE  was  based  on  generally  
accepted clinical, histological and immunofluorescence findings and that of SCLE on the 
revised description (Sontheimer 2005). The diagnosis of SLE was based on the fulfilment of 
the 1982 revised ACR classification criteria (Tan et al. 1982), including the presence of 
systemic manifestations together with positive serology and skin manifestations, and was 
always verified by a rheumatologist. To confirm the correct diagnosis, a skin biopsy was 
taken from 294/310 (95%) of the patients. The diagnosis was based on clinical and laboratory 
findings in those patients from which the biopsy was not obtained, because of the lack of skin 
lesions at the time of investigation (especially in SLE), or because the biopsy was 
inconclusive. The participating patients were clinically examined by three dermatologists (S. 
Koskenmies, T. Hasan and J. Panelius) and interviewed using a structured questionnaire. A 
total of 356 anonymous control individuals (49% women) comprised unaffected spouses or 
common-law spouses of patients and a collection of unrelated healthy individuals. The 
clinical characteristics of the patients are summarised in Table 5, while a more comprehensive 




Table 5. Clinical characteristics of the Finnish patient cohorts used in this study. 










Females 76 91 93 94 
Mean age at onset (range) 42 (15-77) 54 (14-89) 36 (8-85) 29 (1-66) 
Mean age at diagnosis (range) 45 (17-77) 56 (15-89) 40 (13-86) 33 (6-72) 
Butterfly rash 11 17 72 51 
Discoid rash 92 10 44 10 
Annular SCLE lesions 1 43 12 na 
Psoriasiform SCLE lesions 1 63 22 na 
Photosensitivity 65 81 80 69 
Mouth ulcers 4 0 18 18 
Arthritis 2 7 66 83 
Renal involvement 1 0 20 30 
Leukopaenia 7 14 37 68 
Thrombocytopaenia 5 5 17 16 
Elevated antinuclear 
antibodies 
28 79 98 na 
Ro/SSA antibody 
positivity1 
25 81 66 na 
La/SSB antibody 
positivity1 
4 39 31 na 
Double-stranded DNA antibody 
positivity 
9 5 37 na 















1.3 Finnish family cohort (Study III) 
The Finnish  family  cohort  includes  192  families,  with  a  total  of  236  SLE patients  and  their  
unaffected relatives. According to the estimated prevalence of SLE in Finland (Helve 1985), 
80-85% of patients requiring hospitalisation were contacted at the time of recruitment, which 
began in 1995. Patients with a positive family history of SLE and fulfilling the ACR 
classification criteria (Tan et  al. 1982) were asked to participate in the study together with 
their unaffected and/or affected family members. All subjects were interviewed by the same 
rheumatologist (H. Julkunen) and their medical records were reviewed. Blood samples were 
obtained from a total of 252 families, of which 53 were multiply affected by SLE and the 
remaining were families of sporadic patients. A proband from each family was analysed in 
combination  with  sporadic  SLE  cases  from  the  Finnish  case-control  cohort  in  Study  III  
(Hellquist et al. 2009). The clinical characteristics of the patients are described in Table 5 and 
more detailed information is given by Koskenmies et al. (2001). 
 
1.4 Swedish case-control cohort (Study IV)  
The Swedish case-control cohort is a large collection of patients with different connective 
tissue diseases and has been used for replication in Study IV. Swedish patients participating in 
a study assessing the incidence and prevalence of SCLE in Stockholm in 1996-2002 reported 
their occurrence of photosensitivity and skin symptoms in a questionnaire. Patients were 
examined clinically (K. Popovic and F. Nyberg) at the Department of Dermatology, Danderyd 
Hospital, Stockholm, and clinical data were completed based on patient history and medical 
records. The diagnoses of DLE and SCLE were based on clinical and histological features and 
those of SLE, SS and undifferentiated connective tissue disease were based on generally 
accepted criteria (Mosca et al. 1999; Tan et al. 1982; Vitali et al. 2002). The collection of this 
material has been recently described in detail (Popovic et al. 2007b). 
 
Another Swedish sample set, consisting of patients with SS fulfilling the revised European 
criteria for diagnosis (Vitali et al. 2002) and attending the Karolinska University Hospital, 
Stockholm in 1998-2008, was also used for replication. The diagnosis was verified by a 
combination of clinical examination by rheumatologists or medical doctors and a 
questionnaire. In total, there were 164 Swedish patients, out of which 134 were positive for 
Ro/SSA autoantibodies that were detected as described (Popovic et al. 2007b; Tengner et al. 
1998). The clinical characteristics of the Swedish patients are presented in Table 6. The 
population-based 295 control individuals (90.5% women) consisted of samples from the 











Table 6. Clinical characteristics of the Swedish patient cohorts used in this study. 
Percentage (%) of patients with each phenotype is shown. 
 
Connective tissue 
disease patients (n=91)1 
Sjögren’s syndrome 
patients (n=73)2 
Female 91 95 
Mean age at onset (range) 58 (18-83)3 na 
Mean age at diagnosis (range) na 52 (20-87) 
Butterfly rash 13 na 
Discoid rash 19 na 
Annular SCLE lesions 14 na 
Psoriasiform SCLE lesions 0 na 
Photosensitivity 100 na 
Mouth ulcers na na 
Arthritis 5 23 
Renal involvement 5 4 
Leukopaenia na 18 
Thrombocytopaenia na 3 
Elevated antinuclear antibodies 74 55 
Ro/SSA antibody positivity 100 59 
La/SSB antibody positivity 38 38 
Double-stranded DNA antibody positivity 13 na 
1Ro/SSA positive patients without signs of systemic inflammation=21, DLE=2, SCLE=8, 
SLE=31, SS=23, undifferentiated connective tissue disease=6 from the study of Popovic et al. (2007b) 
2SS patients from Prof. Marie Wahren-Herlenius, Dept. of Medicine, Rheumatology Unit, 
Karolinska Institutet, Solna, Sweden 
3Mean age at initial testing for Ro/SSA autoantibodies (Popovic et al. 2007b) 
















1.5 Tissue samples (Studies II and V) 
All tissue samples were archival formalin-fixed, paraffin-embedded skin sections obtained 
from the Department of Dermatology and HUSLAB, Helsinki University Central Hospital. 
The diagnoses were based on clinical and laboratory data (S. Koskenmies) and confirmed 
histologically by an experienced dermatopathologist (L. Jeskanen). 
 
Study II In order to study TYK2 expression in skin, lesional biopsies were obtained from 25 
patients,  of  whom  seven  had  DLE,  seven  SCLE  and  11  SLE.  Tissue  sections  from  normal  
skin (n=5), kidney (n=4), prostate cancer (n=3) and squamous cell carcinoma (n=3) were 
selected as positive controls based on experimental evidence (Ide et al. 2008; Nishio et al. 
2001) and expression profile (NCBI UniGene; 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene). A total of 22 patients, of whom eight 
had DLE, six SCLE and eight SLE were used to investigate the cutaneous expression of IRF5. 
Tissue sections from normal skin (n=3), placenta (n=2), breast cancer (n=2) and lymph nodes 
(n=2) were selected as positive controls based on IRF5 gene  expression  profile  (NCBI  
UniGene). 
 
Study V The tissue expression of MMP-3, -7, -9, -10, -14, -19 and -26 as well as their 
endogenous inhibitors TIMP-1 and -3 was examined in a total of 57 patients (58 samples 
altogether), of whom 20 had DLE, 17 SCLE and 20 SLE. To confirm that the expression of 
MMPs studied was not induced by mere UVA or UVB radiation without evidence of lupus, 
photoprovocated skin samples obtained from healthy volunteers 3-5 days after the last 
repeated provocation with 100 J UVA or with 1.5 minimal erythema dose of UVB (Saarialho-





















The methods used in this study have been described in detail in the original publications 
(Table 7). Some of the methods are presented in more detail below. 
 
Table 7. Methods used in this thesis. 
Method Kit / Manufacturer / Reference Study 
Laboratory procedures   
DNA extraction Flexigene DNA kit, Qiagen GmbH Hilden, Germany 
Puregene blood kit, Gentra Sytems Inc., Minneapolis, 
MN, USA 
(Lahiri and Nurnberger 1991; Miller et al. 1988)  
II, III, IV 
Immunohistochemistry StreptABComplex/HRP Duet, Mouse/Rabbit, 
DakoCytomation, Glostrup, Denmark 
Vectastain Elite ABC kit, Vector laboratories, Burlingame, 
CA, USA 
(Saarialho-Kere et al. 1993) 
II, V 
TUNEL method ApopTag Peroxidase In Situ Apoptosis Detection Kit, 
Chemicon International, Temecula, CA, USA 
(Airola et al. 1997) 
V 
Histopathological analysis (Jerdan et al. 1990) 




Sequenom Inc., San Diego, CA, USA 
http://www.sequenom.com 
(Jurinke et al. 2002) 
II, III, IV 
PCR assay design SpectroDESIGNER, Sequenom Inc. II, III, IV 
Extension reaction cleaning SpectroCLEANER, Sequenom Inc. II, III, IV 
Microsatellite genotyping (Dideberg et al. 2007; Koskenmies et al. 2004) unpublished 
data 
Analysis programs   
MassARRAY mass 
spectrometer 
Bruker Daltonik GmbH, Bremen, Germany II, III, IV 
SpectroTYPER RT v. 3.3.0 Sequenom Inc. II, III, IV 
Molecular Dynamics 
MegaBACE™ 1000 




Profiler v. 2.0 






Method Kit / manufacturer / reference Study 
Statistical softwares    
PedCheck (O'Connell and Weeks 1998) III 
Haploview v. 4.0 (Barrett et al. 2005) II, III, IV, 
unpublished 
data 
SNPHAP v. 1.3 (Clayton 2002) 
http://www-gene.cimr.cam.ac.uk/clayton/software/ 
II 
SPSS v. 12.01, 13.0, 15.0 
 
SPSS Inc., Chigago, IL, USA I, II, II, IV, V 
STATA v. 8.0 Stata, College Station, TX, USA 
(Melen et al. 2006) 
III 
VassarStats Richard Lowry, Poughkeepsie, NY, USA 
http://faculty.vassar.edu/lowry/VassarStats.html 
V 
GraphPad Prism v. 4.03 GraphPad Sotfware, La Jolla, CA, USA II, III, IV, 
unpublished 
data 
Power for Association With 
Error program v. 1.2 
(Gordon et al. 2002; Gordon et al. 2003) 
http://linkage.rockefeller.edu/pawe/ 





2.1 Data storage and management 
Blood vials and DNA tubes were equipped with corresponding sample identification numbers. 
No one other than the immediate local project members had access to the personal 
identification code. At the genotyping core facility an automated sample processing and 
tracking software platform in a laboratory information management system (Nautilus LIMS) 
was used. Samples were tracked using barcode labels and nonpersonally identifiable sample 
tracking numbers. The genotype data and information on affection status and clinical features 
were stored in file formats compatible with analysis software. The following investigators had 
routine access to different data sets: T. Järvinen, A. Hellquist, S. Koskenmies and P. Onkamo 








2.2 DNA extraction (Studies II-IV) 
Blood was collected in ethylenediaminetetraacetic acid (EDTA) vials.  Genomic DNA of the 
sporadic patients and control individuals was extracted from whole-blood samples by 
standard nonenzymatic methods using commercial kits according to manufacturer’s 
instructions. DNA of the SLE families was extracted using the protocol by Lahiri and 
Nurnberger (1991). The traditional salting out method (Miller et al. 1988) was employed for 
Swedish samples. 
 
2.3 Marker selection (Studies II-IV and unpublished data) 
Studies II and III After careful review of SLE literature published prior to GWASs, a total of 
20 SNPs (Appendix Table 1) were selected for genotyping in the following genes: IRF5, 
TYK2, CRP, FCGR2A, CTLA4, PDCD1, GIMAP5, NOD2, PTPN22 and TNF- . All these 
genes and their respective SNPs have shown either significant linkage or association with 
SLE in previous studies (De Jager et al. 2006; Duerr et al. 2006; Graham et al. 2006; Graham 
et al. 2007; Graham et al. 2007; Hellquist et al. 2007; Karassa et al. 2002; Kaufman et al. 
2006; Prokunina et al. 2002; Russell et al. 2004; Sigurdsson et al. 2005; Suarez et al. 2005; 
van Heel et al. 2002). A subset of Finnish family material, consisting of 109 SLE patients and 
121 unaffected pedigree members, was studied previously for association to IRF5 and TYK2 
(Sigurdsson et al. 2005), but with partly different markers. Thus these genes could be 
considered positive controls for association in extended SLE sample set in Study III. 
 
Out of the selected markers, rs2004640 in IRF5, rs1205 in CRP, rs2066843 in NOD2 and 
rs2476601 in PTPN22 failed to meet our genotyping quality criteria and were thus excluded 
from further analyses. The NOD2 SNP rs2066845 was found to be monomorphic (MAF 
<0.5%) resulting in exclusion of this marker and the remaining NOD2 marker rs2076756 was 
genotyped only in families. The assay design for the polymorphisms in TNF-  (rs1800629 
and rs1800630) failed because of too many adjacent SNPs and therefore these polymorphisms 
were not included in the genotyping. Thorough investigation of GIMAP5 markers has been 
recently conducted in an independent study of the family material (Hellquist et al. 2007). 
 
Study IV Eleven SNPs (Appendix Table 2) within the ITGAM region showing replicated and 
robust association to SLE across several populations were selected for genotyping based on 
published results (Harley et al. 2008; Hom et al. 2008; Nath et  al. 2008). The markers 
rs6565227 and rs1143678 had a success rate below a study inclusion threshold (<85%) and 
were thus excluded. 
 
Unpublished study Altogether 37 additional SNPs, and one indel polymorphism in IRF5-
TNPO3 (Appendix Table 2) were genotyped alongside the ITGAM-ITGAX locus in lupus 
patients with cutaneous manifestations. Priority was given to genes and loci showing the 
strongest evidence of association with SLE in recently published GWASs: STAT4, BANK1, 
TNFAIP3, IRF-TNPO3, BLK-FAM167A, KIAA1542, 1q25.1 and PXK (Graham et al. 2008; 




suggestive association in one GWAS (Harley et al. 2008) was also included in the study 
(ATG5, ICA1, LYN, XKR6 and SCUBE1). At each locus, SNPs providing the best association 
signal in previous GWASs together with those already known to be of functional relevance, 
or previously found strongly associated to SLE, were selected. 
 
2.4 Statistical power analysis (Studies II-IV)  
Power calculations to detect associations to studied risk variants were performed assuming 
reported risk parameters in the original studies (Han et al. 2009b; Sigurdsson et al. 2005; 
Sigurdsson et al. 2008a) at a significance level of 0.05. The power of an allelic test to detect 
association to IRF5 with  an  OR of  1.45  was  92% in  DLE,  49% in  SCLE and 97% in  SLE.  
Patients with DLE had a maximum power of 57% to identify association to TYK2 (OR=1.40); 
the corresponding numbers for SCLE and SLE patients were 22% and 70%, respectively. The 
average power to detect association of ITGAM variants in different patient cohorts was 84% 
in DLE, 42% in SCLE, 91% in SLE and 80% in Swedish patients when a minor allele 
frequency of 0.118% in controls and an OR of 1.7 were used. 
 
2.5 Genotyping (Studies II-IV and unpublished data) 
In Studies II-IV, the Sequenom genotyping platform was employed. The Sequenom 
methodology utilises matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) 
mass spectrometry for detection of resulting polymerase chain reaction (PCR) products. For 
allele-specific primer extension (Jurinke et al. 2002) the iPLEX protocol was chosen, in 
which up to 40 SNPs can be multiplexed in a single PCR. The genotyping amplification 
reactions were performed as described in detail in Hellquist et al. (2007) with small 
modifications. All PCR and extension assays were designed using SpectroDESIGNER 
software. Unincorporated dNTPs were dephosphorylated by addition of shrimp alkaline 
phosphatase enzyme to each sample. Extension reactions were then conducted together with 
low and high mass primers and the Mass EXTEND Reagents Kit before being cleaned using 
SpectroCLEANER. Desalted primer extension products were analysed by a MassARRAY 
mass spectrometer. The resulting mass spectra was analysed for peak identification using the 
SpectroTYPER RT for iPLEX assays. All genotypes were independently verified by two 
investigators. Genotyping was performed as a core service at the Mutation Analysis Facility, 
Karolinska Institutet, Huddinge, Sweden (http://www.maf.ki.se).  
 
The  quality  control  of  the  SNP  genotyping  assays  was  performed  according  to  standard  
operating procedures at the genotyping core facility. Each genotyped assay was validated to 
assure genotyping consistency and quality by comparing genotype concordance from the 
genotyping on our platform in a set of 14 CEPH trios (Centre d’Etude Polymorphisme 
Humaine, Utah residents with ancestry from northern and western Europe) with genotypes 
available through the HapMap consortium (http://www.hapmap.org). Internal concordance 
was analysed on 14 additional unrelated individuals of Caucasian descent. Hardy-Weinberg 
equilibrium (HWE) was analysed in a total of 55 unrelated individuals to ensure that each 




samples) with genotypes for each assay was accounted for, where assays showing more than 
50% positivity were excluded. Success rate of all assays was required to be 85%. Assays not 
fulfilling the quality criteria were excluded from further genotyping. In the following 
genotyping, 90 samples from each individual sample set were genotyped twice and analysed 
for concordance to assure genotyping consistency. In addition to analysing HWE, negative 
controls with genotypes and success rate as in validation step, PedCheck (O'Connell and 
Weeks 1998) was used to detect Mendelian inconsistencies in the family material and markers 
showing >10% inheritance errors were excluded. 
 
2.6 Association analyses (Studies II-V and unpublished data) 
Haploview program (Barrett et al. 2005) was used to explore descriptive genotyping data. 
Allele and haplotype frequencies were calculated, and LD patterns assessed through pairwise 
D’  and  r2 values.  In  addition  to  Haploview,  SNPHAP software  (Clayton  2002)  was  used  to  
construct individual CTLA4 haplotypes for DLE patients (Study II). Allele and haplotype 
associations were investigated using a chi-squared ( 2) test as implemented in Haploview and 
two-sided P-values reported. ORs with corresponding 95% confidence intervals were 
estimated. In Studies II and IV, permutation tests (10,000 iterations) were performed for 
correction of multiple testing. Study III was a replication study, in which nominal P-values 
less than 0.05 were considered significant, and empirical P-value to confirm observed 
associations was obtained by the permutation approach (10,000 iterations). 
 
2.7 Statistical analysis (Studies I-V) 
Study I To create an overall picture of differences in clinical features, autoimmune diseases 
and laboratory abnormalities between different LE subtypes or the sexes, several types of 
comparisons were made. Group frequencies of binary and categorical traits were compared by 
a  2 test or Fisher’s exact test, where the asymptotical properties for the 2 test  were  not  
appropriate. In addition, comparisons to population frequencies of smoking and RA were 
performed by nonparametric binomial test. Between-group comparisons of continuous and 
normally distributed variables were compared by t-test and one-way ANOVA accompanied 
by post hoc tests, where an overall difference had been found. The Mann-Whitney U-test 
(comparisons between two independent groups) and Kruskall-Wallis test (comparison 
between more than two independent groups) were used for normal traits. Because of the 
exploratory nature of Study I, correction for multiple testing was only applied in the analysis 
of variance post hoc tests, where Sheffe’s method was used as implemented in the SPSS 
statistical package. Patients with missing values were excluded from frequency tables, 









Clustering analysis was employed to divide patients computationally into groups based on 
similarities in various clinical manifestations and laboratory findings (Table 8) without 
knowing their original diagnosis of LE subtypes. Patients from Tampere University Hospital 
were excluded from analysis because of missing data for Ro/SSA and La/SSB autoantibodies, 
and four additional patients were left out due to incomplete data in some variables. Clustering 
methods are exploratory tools designed to reveal natural clusters or groupings within a data 
set that would otherwise not be apparent. In Study I, the grouping was made on the basis of 
similarities  and  differences  in  the  clinical  data  and  other  features  of  the  patients,  where  the  
most similar individuals form the clusters. The SPSS Two-Step algorithm was applied to the 
clinical data. The actual diagnoses were intentionally left out to obtain the natural grouping of 
the disease subtypes. The Two-Step algorithm is able to handle both categorical and 
standardised continuous variables, and the optimal number of clusters is selected 
automatically by comparing the values of a model-choice criterion across different clustering 
solutions. The grouping is based on the similarity between the individuals in the array of 
features; the similarity, however, is evaluated with a log-likelihood method. The likelihood 
measure places a probability distribution on the variables. Continuous variables are assumed 
to be normally distributed, whereas categorical variables are assumed to be multinomial. All 
variables are assumed to be independent. 
 
Study III A multiple logistic regression model was used to estimate the gene-gene interaction 
between IRF5 and TYK2 SNPs in SLE patients by adding an interaction term between the 
genotypes of interest, as described previously (Melen et al. 2006). A model-free coding with 
variables for common homozygotes, heterozygotes and rare homozygotes was used as a first 
approach. For SNPs with too few rare homozygotes, dominant coding was used. P-values 
were obtained by likelihood-ratio tests that measure the null-hypothesis of no interaction 
between the models with and without interaction term. Observed P-values estimate a 
departure from a multiplicative interaction model on the OR scale indicating whether the 
effect (OR) of one genotype is altered by the effects of another genotype.  
 
Sudy V Chi-squared test or Fisher’s exact test, when appropriate, were employed to compare 
the number of MMP-positive samples and histological parameters in different diagnostic 
groups. The Mann-Whitney U-test and Kruskall-Wallis test were used for comparing the 















Table 8. Clinical variables used in cluster analysis and to study association to  
IRF5, TYK2 and ITGAM. 
Clinical variable Study I Study II Study III2 Study IV3 
Sex     
Malar rash     
Disseminated ACLE lesions     
DLE lesions     
Annular or psoriasiform 
SCLE lesions  
    
Other LE-nonspecific 
cutaneous manifestations 
    
Self-reported photosensitivity     
Arthritis     
Serositis     
Renal involvement     
Neuropsychological symptoms     
General symptoms     
Raynaud’s phenomenon     
Sjögren’s syndrome     
Anaemia     
Leucopaenia     
Lymphopaenia     
Thrombocytopaenia     
Hypersedimentation     
Complement 3 or 4 level 
under reference value 
 C4 C4  
Elevated ANA or ENA 
antibody titres 
   ANA 








Use of oestrogen     
Smoking     
Age at onset     
Number of positive 
ACR criteria 
    
1Ro/SSA and La/SSB information was not available for patients from Tampere UniversityHospital, 
and probands from SLE families. 
2Family probands had imperfect data on complement 4 values, anaemia and serositis.  
3Information was not available on smoking, hypersedimentation and complement levels for probands 




Subphenotype analysis (Studies II-IV) The  association  of  IRF5, TYK2 and ITGAM risk 
variants with clinical characteristics was investigated by stratifying patients into subgroups 
according to the presence or absence of the manifestations listed in Table 8. In Study II, DLE 
patients were further grouped into carriers and noncarriers of the high risk CTLA4 haplotype 
GGCGA in order to study whether these two groups differ clinically. The variables selected 
for analysis were those that differentiated the patients most by clustering method in the 
descriptive clinical study of our patient cohort (Study I; Koskenmies et al. 2008) or have been 
reported to show association (Baechler et  al. 2003; Namjou et al. 2002b). Ro/SSA 
autoantibody information was not available for patients from Tampere University Hospital 
and SLE families; neither had the family probands data available on the following traits: 
complement concentrations, anaemia, serositis, smoking at disease onset and 
hypersedimentation. 
 
The  genotype  (IRF5, TYK2, ITGAM) or haplotype (CTLA4) frequencies in cases with and 
without the certain feature were compared. For categorical variables, the significance of 
individual genotypes or haplotypes was assessed by 2, Fisher exact test or logistic regression. 
For  continuous  variables,  two-way  ANOVA  was  used.  In  Studies  II  and  III,  two-tailed  P-
values less than 0.05 after Bonferroni multiple testing correction were considered significant. 
In Study IV, two-tailed P-values less than 0.05 were considered significant without correction 
for multiple testing, since the clinical variables are known to correlate and adjustment would 
likely be overly conservative (Hom et al. 2008). 
 
2.8 Immunohistochemistry (Studies II and V) 
Immunohistochemical analyses were performed to study the expression of multiple MMPs as 
well as TIMPs, TYK2 and IRF5 proteins (Table 9) in involved and healthy skin as well as 
other relevant tissues. Immunostaining of tissue samples was carried out using the enzymatic 
avidin-biotin-peroxidase complex technique, in which biotinylated secondary antibody 
interacts with a complex of avidin-biotin peroxidase bound to primary antibody. 
Diaminobenzidine (DAB), aminoethylcarbazole or NovaRED peroxidase (Vector 
laboratories, Burlingame, CA, USA) were used as chromogenic substrates and Mayer’s 
hematoxylin as counterstain, as described in detail elsewhere (Saarialho-Kere et al. 1993). 
Following standard deparaffinisation by xylene treatment and decreasing alcohol series, 
endogeneous peroxidase activity was blocked by incubation with 3% H2O2 for 10 min in PBS 
at room temperature. Sections were pretreated for 10-30 min when necessary. Primary mono- 
or polyclonal antibodies (Table 9) were applied on slides and incubated for 45 min - 2 hours 
at 37 C or overnight at 4 C in a humified chamber. Control experiments were performed 
using rabbit and mouse preimmune serum as primary antibodies at equivalent dilutions (Table 
9). Immunohistochemical specimens were analysed by four different investigators (T. 
Järvinen, P. Kanninen, L. Jeskanen and U. Saarialho-Kere) under a light microscope at 200x 
magnification. Semiquantitative immunoreactivity grading was based on positive staining in 
the epidermis and dermis and scored as follows: 0<10 positive cells, 1=10-20 positive cells, 





Table 9. Antibodies used in immunohistochemistry. 
Antibody Source Dilution  Pretreatment 
MMP-3 ab32607, Abcam 1:85 +95 C water bath in citrate buffer 
MMP-7 IM40L, Calbiochem 1:100 +95 C water bath in citrate buffer 
MMP-9 MS-569, LabVision 1:75 Trypsin 10mg/ml 
MMP-10 NCL-MMP10, 
Novocastra laboratories 
1:300 Trypsin 10 mg/ml 
MMP-14 MT1-MMP (current RB-1544), 
LabVision 
1:400 No pretreatment 
MMP-19 PC374, Oncogne 1:45 No pretreatment 
MMP-26 Prof. Keiichi Isaka 
(Ahokas et al. 2005) 
1:150 +95 C water bath in citrate buffer 
TIMP-1 IM63, Calbiochem 1:100 +95 C water bath in citrate buffer 
TIMP-3 IM43L, Calbiochem 1:500 +95 C water bath in citrate buffer 
TYK2 sc-169, SantaCruz Biotechnology 1:500 +95 C water bath in citrate buffer 







1 Smoking characterises DLE (Study I) 
Altogether three hundred and ten DLE, SCLE and SLE patients with LE-specific cutaneous 
manifestations were recruited using patients’ charts from institutional databases and during 
routine control visits. Clinical data collected from the medical records included the 11 ACR 
criteria completed by more detailed information on the cutaneous and general symptoms and 
the year of diagnosis. Salient clinical manifestations and laboratory findings are summarised 
below, while more detailed information is presented in Study I and Tables 2-6 therein 
(Koskenmies et al. 2008). 
 
The mean age (standard deviation) at onset was 42 (15) years in DLE, 55 (19) years in SCLE 
and 31 (16) years in SLE and the difference between patient groups was significant 
(P=0.001). Patients with DLE and SCLE were characterised with typical discoid, annular or 
psoriformic lesions, whereas malar rash, oral ulcerations and disseminated ACLE lesions 
were most often seen in SLE patients. Only a few patients with DLE also had ACLE lesions 
and one third of SCLE patients had malar rash. Photosensitivity was self-reported in most 
cases, and characterised all groups, in particular SCLE patients, of whom 87% reported sun-
induced LE rash or worsening of existing LE rash in sunlight. Provocative phototesting (either 
UVA and/or UVB) was positive in 21% (8/38) of tested patients. Raynaud’s phenomenon was 
the most frequent nonspecific LE skin manifestation observed and typically concurrent with 
SLE, whereas other nonspecific manifestations (vasculitis, alopecia, urticaria and livedo 
reticularis) were rare in all groups. 
 
In general, laboratory value abnormalities were most often detected in patients with SLE. 
Interestingly, lymphopaenia and hypersedimentation were common in all patients, although 
with higher frequencies in SCLE (44% and 56%, respectively) and SLE (52% and 71%, 
respectively) patients. As expected, patients with DLE and SCLE had less immunological 
defects compared to SLE patients. However, ENA autoantibodies and especially Ro/SSA 
autoanbodies showed elevated titre levels more often in SCLE (83%) than in SLE (62%) 
patients, while less than 30% of DLE patients were positive for ENA autoantibodies. In 
contrast, ANAs were detected slightly more frequently among SLE (96%) than in SCLE 
(84%) cases. Association of positive ENA and ANA tests with certain clinical features was 
further investigated. There was a tendency of Ro/SSA and La/SSB autoantibody positive 
patients to report photosensitivity (P=0.03) and ANA positivity coincided with malar rash, 
disseminated ACLE lesions and cutaneous manifestations of SCLE. 
 
Systemic manifestations are rarely seen in other patients with LE than those with SLE, in 
which arthritis (68%) was the most commonly observed. Three patients with renal 
involvement  and  one  with  serositis  were  found in  the  DLE group,  while  none  of  the  SCLE 
patients presented with these defects. Approximately one fourth of SLE patients had renal 




proteinuria and haematuria, were rare among DLE and SCLE cases, whereas around 20% of 
SLE cases had proteinuria or haematuria at some point of their disease course. Neurological 
findings were rare in all patient groups.  
 
Personal history of autoimmune disease other than LE was more often reported by SCLE and 
SLE than DLE patients. Of the concomitant autoimmune diseases, SS was the most common 
followed by autoimmune thyroid disease in all subgroups. However, these diseases were 
observed at substantially higher frequencies in SCLE (16% and 13%, respectively) and SLE 
(22% and 11%, respectively) than in patients with DLE (2% and 3%, respectively).  
Interestingly, the prevalence of RA seemed to be increased among SCLE patients (6%). 
However, age/gender-matched comparison showed no difference between cases and the 
background population, which has a prevalence of 1% for RA (Hakala et al. 1993). 
 
High  frequency  of  smoking  was  characteristic  to  all  patient  groups.  At  the  time  of  first  
symptoms, 57% of DLE, 35% of SCLE and 34% of SLE patients smoked daily. Notably, as 
many as 51% of women with DLE were smokers indicating that the high proportion of 
smoking in this subgroup is not due to male predominance (62% were smokers). Smoking 
was more prevalent in LE patients compared with the population in general: 63% of female 
and 57% of male patients at age 25-44 years smoked daily, while the corresponding numbers 
were 22% and 35%, respectively, in the age/gender-matched background population 
(Statistics Finland 2005). 
 
Clustering analysis showed three separate clusters not entirely coinciding with clinical 
subgroups (Figure 4). When the cluster-membership of the patients was cross-checked against 
diagnoses,  it  was  found  that  cluster  3  was  an  equal  combination  of  patients  with  DLE  and  
SCLE (35 and 29, respectively), whereas cluster 1 represented SLE patients (46/56 members) 
and cluster 2 consisted of DLE patients (99/102 members). Of particular interest is the 
observation that daily smoking was one of the characteristics that differentiated cluster 2 from 
other clusters. Other important differences between the clusters were found in variables such 
as elevated titre levels of ENA (especially Ro/SSA autoantibodies) and ANA, malar rash, 
discoid lesions, disseminated ACLE lesions, serositis, Raynaud’s phenomenon, arthritis, low 
serum complement 3 and 4 concentrations, and a number of ACR criteria. Based on the 
results, haematological and immunological findings seemed to account more for cluster 





Figure 4. The cluster sizes and the most important differentiating variables with their representative frequencies 
for each cluster. The mean of American College of Rheumatology criteria was 4.9, 2.4 and 3.0 for clusters 1, 2 
and 3, respectively.  
 
 
2 IRF5 and TYK2 confer risk for DLE and SCLE (Study II) 
A panel of 15 SNPs in six genes implicated previously in SLE pathogenesis was successfully 
genotyped in a total of 219 patients with DLE or SCLE and their respective control 
individuals. IRF5, TYK2 and CTLA4 were  further  investigated  for  association  with  relevant  
clinical characteristics (Table 8). In addition, the expression of IRF5 and TYK2 proteins in 
lesional skin was studied employing immunohistochemistry.  
 
Single  allele  association  results  in  DLE and  SCLE patients  are  presented  in  Table  10.  DLE 
and  SCLE patients  carrying  the  A allele  of  IRF5 marker rs10954213 had increased disease 
risk compared to controls (OR=1.40, 95% CI=1.06-1.86 and OR=1.87, 95% CI=1.09-3.21, 
respectively). TYK2 showed  association  only  to  DLE,  and  the  lack  of  association  in  SCLE  
may  reflect  the  modest  size  of  the  particular  patient  cohort.  Significant  association  was  
observed in DLE patients carrying the C allele of TYK2 marker rs2304256 (adjusted P=0.04), 
while two other markers studied did not reach significant association. However, on the 
haplotype level, the GCA allele combination of three genotyped TYK2 markers was found to 
be associated with increased risk of DLE (P=0.05, OR=1.43, 95% CI=1.07-2.0). None of the 




demonstrated highly increased risk in patients with DLE (P=0.03, OR=2.51, 95% CI=1.25-
5.04). 
 
Other genes studied, namely FCGR2A, PDCD1 and GIMAP5, did not show association with 
CLE. Interestingly, the A allele of rs1801274 in FCGR2A was abundant among patients with 
DLE, whereas in contrast, SCLE patients were carriers of the G allele. The G allele of 
rs11568821 in PDCD1 was  slightly  more  common in  patients  than  in  controls.  In  line  with  
our previous report on Finnish SLE trios (Hellquist et al. 2007), the most frequent GIMAP5 





Table 10. Single allele and haplotype association results in DLE, SCLE and SLE patients. 
  DLE (n=177) SCLE (n=42) SLE (n=277) 






















Case freq P-value OR (95% CI) 
FCGR2A rs1801274 A 0.50 0.52 0.51  G 0.50 0.59 0.14  
G 0.50 0.54 0.15 
 
CTLA4 rs231775 G 0.50 0.55 0.19  G 0.51 0.56 0.34  
A 0.49 0.51 0.47 
 
CTLA4 rs3087243 A 0.35 0.36 0.61  G 0.66 0.71 0.37  
G 0.66 0.66 0.87 
 
CTLA4 rs231726 T 0.46 0.47 0.81  T 0.46 0.54 0.19  
C 0.54 0.56 0.53 
 
CTLA4 rs231727 A 0.46 0.47 0.80  A 0.46 0.54 0.19  
G 0.54 0.56 0.58 
 
CTLA4 rs1991416 A 0.53 0.54 0.95  G 0.47 0.51 0.44  
A 0.53 0.55 0.49 
 
CTLA4  GGCGA 0.02 0.05 0.0065* 2.51 (1.25-5.04)           
PDCD1 rs11568821 G 0.92 0.94 0.26  G 0.92 0.95 0.39  
C 0.92 0.95 0.06 
 
IRF5 rs10954213 A 0.62 0.69 0.017* 1.40 (1.06-1.86) A 0.62 0.75 0.022 1.87 (1.09-3.21) 
A 0.62 0.70 0.0043 1.42 (1.12-1.81) 
GIMAP5 rs759011 T 0.38 0.38 0.95  C 0.62 0.63 0.87       
GIMAP5 rs1046355 T 0.38 0.38 0.95  C 0.62 0.63 0.87       
GIMAP5 rs6598 G 0.62 0.62 0.82  G 0.61 0.64 0.76       
GIMAP5 rs2286899 T 0.74 0.76 0.61  T 0.74 0.79 0.34       
NOD2 rs2076756           A 0.85 0.84 0.44  
TYK2 rs12720270 G 0.78 0.81 0.20  A 0.22 0.26 0.41  
G 0.78 0.85 0.0031* 1.57 (1.16-2.21) 
TYK2 rs2304256 C 0.69 0.76 0.0117* 1.47 (1.09-1.98) A 0.31 0.33 0.71  
C 0.69 0.79 0.0001* 1.68 (1.29-2.18) 
TYK2 rs12720356 A 0.91 0.98 0.08  A 0.91 0.95 0.23  
A 0.91 0.93 0.07 
 
TYK2  GCA 0.69 0.76 0.0173* 1.43 (1.07-2.00)      GCA 0.69 0.78 0.0002* 1.63 (1.26-2.12) 
TYK2            AAA 0.22 0.15 0.0030* 0.64 (0.47-0.86) 
The frequency of the associated allele in controls and cases is shown, as well as its P-value and odds ratio (OR) with 95% confidence interval (CI). P-values in bold are 
statistically significant (P<0.05) and P-values marked with asterisk remained significant after correction for multiple testing. 
FCGR2A, Fc fragment of IgG, low affinity IIa, receptor (CD32); CTLA4, cytotoxic T-lymphocyte-associated protein 4; GIMAP5, GTPase, IMAP family member 5; IRF5, 




Based on genetic association results, IRF5 and TYK2 were selected for subsequent 
immunohistochemical studies. The results are presented graphically in Figures 1-2 in Study II 
(Järvinen et al. 2010). IRF5 protein expression was observed in the upper keratinocyte layers 
of the epidermis in skin samples obtained from patients with CLE or SLE. Positive staining 
was observed in macrophage-like cells, fibroblast and plasma cells in the dermis, but neither 
in lymphocytes nor in endothelial cells. Normal skin specimens showed positivity in the 
granular and suprabasal layers of the epidermis. Positive immunoreactivity was found in 
plasma cells and macrophage-like cells in lymph nodes and in plasma cells and occasional 
cancer cells in breast cancer specimens. Lymph nodes with squamous cell carcinoma 
metastasis showed positive staining in a subpopulation of cancer cells. Control experiments 
with preimmune IgG did not result in any staining. 
 
In  skin  samples  obtained  from  patients  with  different  subtypes  of  LE,  TYK2  protein  was  
detected in the granular layer of the epidermis and in suprabasal keratinocytes in all 
subgroups. Normal skin specimens taken from healthy controls showed positive staining in 
keratinocytes located in the granular and suprabasal layers. Staining intensity did not differ 
between diseased and normal skin. Within the infiltrating inflammatory cells of LE lesions, 
TYK2 was expressed by macrophage-like cells and neutrophils in the dermis. Fibroblast-like 
cells were also positive in some biopsies. Furthermore, kidney samples showed 
immunoreactivity in neutrophils. One third of squamous cell carcinoma samples showed 
positive staining in basal keratinocytes and occasional inflammatory cells, while no staining 
was seen in invading cancer cells. Control experiments with preimmune IgG did not result in 
any staining. 
 
3 IRF5 and TYK2 show evidence of gene-gene interaction (Study III)  
The SLE case-control material was genotyped in conjunction with SLE families, and a 
proband  from  each  family  was  analysed  together  with  sporadic  cases  to  obtain  maximal  
statistical power to detect associations. Six genes with published prior GWASs and suggested 
to be of importance in SLE susceptibility were studied, including FCGR2A, CTLA4, PDCD1, 
IRF5, NOD2 and TYK2. The disease risk was further studied by estimating epistasis, that is, 
gene-gene interaction. Motivated by our own results (Koskenmies et al. 2008) and previous 
reports (Baechler et al. 2003; Namjou et al. 2002b), patients were stratified by various clinical 
features (Table 8) in order to explore genetic association to these parameters. 
 
Consistent with the original report on SLE (Sigurdsson et al. 2005) and subsequent replication 
studies (Cunninghame Graham et al. 2007; Graham et al. 2007; Graham et al. 2006; Graham 
et al. 2007; Sigurdsson et al. 2008a), we were able to reproduce the association to IRF5 and 
TYK2 in  an  extended  cohort  of  Finnish  SLE  patients  (Table  10).  In  IRF5, the only 
successfully genotyped SNP rs10954213 showed significant association with the disease 
(P=0.0043, OR=1.42, 95% CI=1.12-1.81). Two out of three studied markers in TYK2, 
rs2304256 and rs12720270, reached the level of significant association (P=0.0001, OR=1.68, 
95% CI=1.29-2.18 and P=0.0031, OR=1.57, 95% CI=1.16-2.21, respectively). Haplotype 




association to one risk (OR=1.63, 95% CI=1.26-2.12) and one protective haplotype 
(OR=0.64, 95% CI=0.47-0.86). None of the other genes tested demonstrated association to 
SLE. 
 
Given that both IRF5 and TYK2 are members of the type 1 IFN pathway, a possible gene-gene 
interaction was studied between genotyped markers in these genes. Significant overall 
interaction could be observed between rs10954213 in IRF5 and rs2304256 in TYK2 
(P=0.014). Figure 5 shows that the risk alleles for rs10954213 (AA) and rs230456 (CC) 
contributed most to the overall interaction (P<0.0001) whereas the remaining combinations 
were insignificant. A tendency towards interaction could be observed between rs12720270 





Figure 5. Genetic interaction between TYK2 and IRF5. 2 x 2 table illustrates the interactive effect of TYK2 
rs2304256 and IRF5 rs10954213 in SLE. Individuals homozygous for the rs2304256 risk allele C and the 
rs10954213 risk allele A show significantly increased risk effect compared to individuals homozygous or 
heterozygous for nonrisk alleles. OR (95% CI) for each combination and number of subjects (N) in each 





4 ITGAM is a novel susceptibility gene with high risk estimate for DLE (Study IV) 
ITGAM was identified as a SLE susceptibility gene simultaneously in a traditional case-
control study setting (Nath et al. 2008) and two GWASs (Harley et al. 2008; Hom et al. 
2008). Several replication studies (Han et al. 2009b; Molineros et al. 2009; Yang et al. 2009) 
have been published thereafter, which encouraged us to investigate the role of this gene in the 
pathogenesis of CLE and compare disease risk to that of SLE. A cohort of Swedish patients 
was also included to study the association between ITGAM and Ro/SSA autoantibodies in 
order to replicate recent findings (Yang et al. 2009). Nine out of eleven SNPs were 
successfully genotyped (Appendix Table 2) in three Finnish datasets corresponding to two 
different LE subgroups (DLE and SCLE) and control individuals. Sporadic SLE patients from 
the case-control cohort were analysed together with probands from SLE families in an 
independent study (Hellquist et al.). 
 
The most remarkable result in Study IV was the observation that studied polymorphisms 
associated with even higher risk for DLE (OR-range of 1.65-3.20) compared to that of SLE 
(OR-range of 1.52-2.14) (Table 11). The markers rs1143679, rs9888879 and rs11860650 
contributed to the strongest association signal (P=10-11) among patients with DLE. The same 
markers showed similar tendency in SCLE patients (P=10-2). All other markers tested in DLE, 
except rs9937837, reached a P-value of 10-8 and  an  OR of  2.50.  As  expected,  the  strong  
association of ITGAM with SLE was replicated in Finnish patients (10-3  P 10-6) (Hellquist 
et al.). A haplotype analysis was also performed in each set of samples, but this neither 
improved statistical significance nor added any further information, since most of the detected 
haplotypes were due to individual SNPs and their alleles as detected in single-marker 
analysis. The ATGCATTTC haplotype carrying allele A at rs1143679 accounted most for the 
risk in both DLE (OR=3.33), SCLE (OR=2.01) and SLE (OR=2.19) (see Study IV 
Supplementary material for details) 
 
The association between ITGAM and Ro/SSA autoantibody positivity was further 
investigated. There were altogether 101 Finnish and 134 Swedish Ro-positive patients that 
were separately compared to healthy control individuals. The marker rs1143679 showed the 
strongest association in both cohorts and the observed ORs were overlapping in Finnish (OR-
range of 1.40-2.65) and Swedish patients (OR-range of 1.16-1.80) (Table 12). 
 
Previous reports show that LE and SS have shared susceptibility genes, namely IRF5 and 
STAT4 (Korman et al. 2008; Miceli-Richard et al. 2007; Nordmark et al. 2009). Based on the 
clinical survey in Study I, SS (30/310 patients) was the most common related autoimmune 
disease  in  patients  with  DLE,  SCLE  and  SLE  (Koskenmies et al. 2008). Moreover, a 
substantial proportion of the Swedish patients presented with SS (96/164; Table 6). Therefore, 
after power calculations had shown sufficient power (83%), it was tested whether ITGAM risk 
alleles appear with higher frequency in patients than in controls (Järvinen et al., unpublished 
data). A modest association was found to markers rs1143679 (P=0.002), rs9936831 (P=0.008) 
and rs129288 (P=0.004) in patients with concurrent SS. Risk estimates (OR-range of 1.24-




markers showed borderline or no association (P 10-2; data not shown). Similar to CLE, SLE 
(Hellquist et  al.) and Ro-positive patients, haplotype analysis did not provide any further 
information. However, the same ATGCATTTC haplotype had a predisposing effect (P=0.003, 










DLE (n=177) SCLE (n=42) SLE (n=275)2 
   Freq. Freq. P-value OR (95% CI) Freq. P-value OR (95% CI) Freq. P-value OR (95% CI) 
rs1143679 A/G A 0.10 0.26 4.73x10-11 3.20 (2.23-4.57) 0.19 0.02 2.17 (1.15-4.09) 0.19 8.29x10-6 2.14 (1.52-3.00) 
rs9936831 T/A T 0.10 0.26 2.14x10-10 3.03 (2.13-4.31) 0.18 0.06 1.86 (0.97-3.57) 0.19 1.32x10-5 2.08 (1.49-2.90) 
rs9937837 G/T G 0.24 0.34 6.00x10-4 1.65 (1.24-2.20) 0.26 0.62 1.14 (0.67-1.94) 0.32 1.20x10-3 1.52 (1.18-1.96) 
rs9888879 C/T C 0.10 0.26 7.57x10-11 3.06 (2.16-4.34) 0.18 0.05 1.84 (0.98-3.45) 0.19 1.10x10-5 2.06 (1.49-2.86) 
rs12928810 A/G A 0.10 0.23 8.03x10-8 2.77 (1.89-4.07) 0.15 0.14 1.67 (0.83-3.34) na3 na na 
rs9888739 T/C T 0.10 0.25 2.91x10-10 3.01 (2.12-4.29) 0.18 0.04 1.88 (1.01-3.53) 0.18 7.52x10-5 1.96 (1.40-2.74) 
rs11860650 T/C T 0.10 0.27 3.71x10-11 3.13 (2.21-4.43) 0.18 0.04 1.94 (1.03-3.64) 0.19 3.36x10-5 1.99 (1.43-2.77) 
rs4548893 T/C T 0.15 0.32 1.10x10-10 2.74 (2.00-3.74) 0.21 0.12 1.58 (0.89-2.81) 0.22 9.00x10-4 1.64 (1.22-2.21) 
rs11574637 C/T C 0.15 0.30 2.37x10-9 2.57 (1.87-3.52) 0.21 0.11 1.58 (0.89-2.83) 0.22 5.00x10-4 1.69 (1.25-2.27) 
The frequency of the associated allele in controls and cases is shown, as well as its P-value and odds ratio (OR) with 95% confidence interval (CI). P-values in bold remain 
significant after correction for multiple testing. 
1Minor allele / major allele  
2From the study by Hellquist et al. 




Table 12. ITGAM locus showed evidence of association in Ro/SSA autoantibody positive Finnish and Swedish patients. 










   Freq. Freq. P-value OR (95% CI) Freq. Freq. P-value OR (95% CI) 
rs1143679 A/G A 0.10 0.22 6.61x10 6 2.65 (1.71-4.10) 0.10 0.15 0.04 1.62 (1.03-2.54) 
rs9936831 T/A T 0.10 0.23 1.34x10 5 2.54 (1.65-3.90) 0.11 0.16 0.05 1.54 (0.99-2.39) 
rs9937837 G/T G 0.24 0.30 0.06 1.40 (0.99-2.00) 0.25 0.31 0.10 1.32 (0.95-1.83) 
rs9888879 C/T C 0.10 0.23 6.31x10 6 2.55 (1.68-3.87) 0.11 0.15 0.05 1.55 (1.00-2.40) 
rs12928810 A/G A 0.10 0.18 0.006 1.96 (1.21-3.19) 0.10 0.16 0.01 1.80 (1.14-2.82) 
rs9888739 T/C T 0.10 0.22 1.47x10 5 2.51 (1.64-3.85) 0.11 0.15 0.08 1.48 (0.96-2.31) 
rs11860650 T/C T 0.10 0.23 9.86x10 6 2.54 (1.66-3.87) 0.11 0.14 0.17 1.37 (0.87-2.16) 
rs4548893 T/C T 0.15 0.27 6.96x10 5 2.15 (1.46-3.14) 0.19 0.21 0.43 1.16 (0.80-1.68) 
rs11574637 C/T C 0.15 0.25 4.00x10 4 1.99 (1.35-2.93) 0.16 0.21 0.08 1.39 (0.96-2.04) 
The frequency of the associated allele in controls and cases is shown, as well as its P-value and odds ratio (OR) with 95% confidence interval (CI). 
P-values in bold remain significant after correction for multiple testing. 




5 Several of the GWAS-identified SLE susceptibility genes are replicated in lupus 
erythematosus patients with cutaneous manifestations (unpublished data) 
Multiple new susceptibility genes were identified, and known candidates confirmed for SLE 
in recently conducted GWASs (Graham et al. 2008; Harley et al. 2008; Hom et al. 2008; 
Kozyrev et al. 2008). Thirteen genes (Appendix Table 2) with the strongest evidence of 
association were tested for disease susceptibility in 304 lupus patients with cutaneous 
manifestations. Genes STAT4, BANK1, TNFAIP3, IRF5-TNPO3, BLK-FAM167A and 1q25.1 
locus  showed  significant  associations  both  in  DLE  and  SLE  patients  (Table  13)  whereas  
genes PXK, ATG5, ICA1, XKR, LYN, KIAA1542 and SCUBE1 did not reach statistical 
significance. 
 
All markers in BLK-FAM167A resulted in strong association to DLE (unadjusted P-values of 
10-4 and 10-3), while more modest results were seen in SLE (P=10-2). IRF5-TNPO3, on the 
contrary, showed robust association (10-1  P 10-7)  to  SLE  whereas  borderline  association  
(P=10-2) was demonstrated in DLE patients. IRF5-TNPO3 was the only gene that associated 
with SCLE (P=0.04, OR=1.74, 95% CI=1.02-2.97 for rs729302 and P=0.003, OR=2.12, 95% 
CI=1.28-3.50 for CGGGG indel), possibly reflecting the insufficient sample size of the cohort 
(data not shown). STAT4 and TNFAIP3 showed  similar  patterns  of  association  as  IRF5-
TNPO3. A marginal association was observed to BANK1 and the 1q25.1 locus in patients with 
DLE. In terms of risk estimates, the highest ORs were detected for TFNAIP3 in  all  LE  
subgroups, while other genes showed a smaller increase in disease risk. No improvement was 





Table 13. GWAS-identified genes associating with DLE and SLE patients with cutaneous manifestations. 




























The frequency of associated allele in controls and cases is shown, as well as its P-value and odds ratio (OR) with 95% confidence interval (CI). P-values in bold remained 
significant after correction for multiple testing. 1 DLE patients have success rate <85% for the IRF5-TNPO3 CGGGG indel. BANK1, B-cell scaffold protein with ankyrin 
repeats 1; BLK, B lymphoid tyrosine kinase; FAM167A, family with sequence similarity 167, member A; IRF5, interferon regulatory factor 5; STAT4, signal transducer and 






DLE (n=177) SLE (n=85) 
Freq Freq P-value OR (95% CI) Freq P-value OR (95% CI) 
1q25.1 rs10798269 G 0.68 0.74 0.03 1.39 (1.03-1.85) 0.72  1.23 (0.84-1.77) 
STAT4 rs3821236 A 0.24 0.27  1.18 (0.88-1.60) 0.35 0.004 1.73 (1.19-2.50) 
STAT4 rs7601754 G 0.11 0.13  1.28 (0.86-1.91) 0.11  1.05 (0.60-1.81) 
STAT4 rs7574865 T 0.20 0.26 0.04 1.39 (1.01-1.88) 0.30 0.006 1.70 (1.16-2.49) 
STAT4 rs10181656 G 0.20 0.25  1.33 (0.98-1.81) 0.30 0.007 1.68 (1.15-2.46) 
STAT4 rs7582694 C 0.20 0.25  1.30 (0.95-1.77) 0.31 0.005 1.71 (1.17-2.50) 
BANK1 rs10516487 G 0.68 0.74 0.03 1.39 (1.04-1.86) 0.69  1.08 (0.75-1.56) 
TNFAIP3 rs6920220 A 0.17 0.24 0.01 1.52 (1.11-2.10) 0.24  1.49 (0.99-2.23) 
TNFAIP3 rs10499197 G 0.01 0.03 0.04 2.50 (1.03-6.10) 0.05 0.001 4.18 (1.63-10.71) 
TNFAIP3 rs5029939 G 0.02 0.03  2.01 (0.86-4.68) 0.05 0.005 3.38 (1.38-8.29) 
TNFAIP3 rs2230926 G 0.02 0.03  2.21 (0.93-5.25) 0.05 0.009 3.32 (1.29-8.56) 
TNFAIP3 rs7749323 A 0.02 0.03  2.01 (0.86-4.68) 0.04 0.04 2.66 (1.02-6.98) 
IRF5-TNPO3 rs729302 A 0.62 0.67  3.23 (2.45-4.25) 0.83 3.8x10-7 2.94 (1.91-4.52) 
IRF5-TNPO3 CGGGG indel1 4x CGGGG 0.43 0.49  1.41 (1.05-1.88) 0.61 1.0x10-4 2.08 (1.43-3.04) 
IRF5-TNPO3 rs3807306 T 0.50 0.60 0.002 1.53 (1.18-2.01) 0.60 0.01 1.54 (1.09-2.18) 
IRF5-TNPO3 rs2070197 C 0.15 0.21 0.02 1.48 (1.05-2.09) 0.25 0.002 1.92 (1.27-2.91) 
IRF5-TNPO3 rs10488631 C 0.15 0.20 0.04 1.42 (1.01-2.01) 0.24 0.003 1.87 (1.23-2.85) 
IRF5-TNPO3 rs2280714 T 0.71 0.77  1.32 (0.97-1.79) 0.76  1.29 (0.87-1.92) 
IRF5-TNPO3 rs12539741 T 0.15 0.21 0.03 1.46 (1.04-2.04) 0.27 3.0x10-4 2.08 (1.40-3.10) 
IRF5-TNPO3 rs10279821 C 0.72 0.77  1.31 (0.97-1.77) 0.79  1.49 (0.99-2.24) 
IRF5-TNPO3 rs12537284 A 0.17 0.21  1.32 (0.95-1.84) 0.26 0.009 1.71 (1.14-2.55) 
BLK-FAM167A rs2736340 T 0.24 0.33 0.002 1.60 (1.19-2.13) 0.32 0.04 1.49 (1.02-2.17) 
BLK-FAM167A rs13277113 A 0.23 0.33 0.002 1.61 (1.20-2.16) 0.32 0.03 1.51 (1.04-2.21) 
BLK-FAM167A rs4840568 A 0.24 0.34 9.0x10-4 1.62 (1.22-2.16) 0.33 0.01 1.57 (1.09-2.27) 
BLK-FAM167A rs2618476 C 0.23 0.34 2.0x10-4 1.72 (1.29-2.29) 0.34 0.004 1.72 (1.19-2.48) 




6 ITGAM variants predict skin lesions in SLE (Studies II-IV) 
The association of ITGAM haplotype tagging SNPs (rs9937837, rs9888878, rs4548893 and 
rs11574637) with clinical variables was studied in Finnish DLE and SLE patients that were 
subgrouped according to presence or absence of the features listed in Table 8. A marginal 
association (P=0.05) between rs9937837 and SLE patients with malar and/or discoid lesions 
(179/275 patients) was observed. The marker rs9888879 showed borderline association 
(P=0.02) with renal involvement (76/275) in patients with SLE. No other markers showed 
association to clinical characters among SLE or DLE patients. A similar subphenotype 
analysis was performed for markers in IRF5 and TYK2 genes. However, none of the clinical 
variables tested showed evidence of association with IRF5 or TYK2 risk allele carrier status. 
 
In Study II, it was further sought to study whether the small proportion of DLE patients 
(18/177, 5%) carrying the high risk CTLA4 haplotype GGCGA form a subgroup clinically 
different from DLE patients that are noncarriers of GGCGA. Minor differences, although 
statistically insignificant, were observed between patients with and without the haplotype. 
Patients carrying GGCGA were more often men (40% vs. 22%) and somewhat younger at 
diagnosis (38 years vs. 42 years), they had Raynaud’s phenomenon more often (22% vs. 
14%), low complement 3 values (12% vs. 4%), false positive cardiolipin antibody test (12% 
vs. 4%), arthritis (6% vs. 2%), general symptoms such as fever and fatigue (11% vs. 7%), RA 
(6% vs. 1%) and they smoked more often at disease onset (75 % vs. 55%). 
 
7 Similar MMP expression profile in different subtypes of CLE (Study V) 
Altogether 58 skin specimens from patients with DLE, SCLE and SLE were examined 
histologically and the expression of multiple MMPs and TIMPs in skin lesions of patients was 
evaluated using immunohistochemistry. MMPs known to regulate apoptosis and induced by 
UV radiation were of special interest. Specific clinical, histological as well as 
immunofluorescence data is given in Table 1 in Study V (Järvinen et al. 2007), whereas 
immunohistochemical results are depicted thoroughly below and in Figures 6 and 7 and 
summarised in Table 14. 
 
As  shown in  Figure  6,  (A)  MMP-3 positive  basal  keratinocytes  were  detected  in  regions  of  
inflammation. High numbers of stromal macrophage/fibroblast-like cells and endothelial cells 
showed protein expression as well. (B) MMP-3 was observed below basal keratinocytes in 
photoprovocated samples, resembling the staining pattern of MMP-7 in UV-treated skin 
(Saarialho-Kere et al. 1999). (C) MMP-7 protein expression was detected in epithelial cells 
with basal vacuolisation and oedema in approximately half of the SCLE and SLE samples, 
while very rarely in DLE specimens. 
 
(D) MMP-9 did not contribute to epidermal changes, but positive stromal macrophages and 
occasional neutrophils were detected in all subtypes (Figure 6). (E) When measured both as 
the number of positive samples and average number of cells showing positive staining, MMP-




keratinocytes in all DLE and SLE samples, while a lower number of SCLE specimens showed 
positive immunoreactivity. This may be due to the fact that the hyperplastic epidermis of DLE 
and SLE skin usually had several MMP-10 positive keratinocyte layers, while in SCLE 
patients the epidermis was often atrophic. (F) Almost all the samples showed positive MMP-
10 staining in stromal macrophage/fibroblast-like cells. No positive staining was seen in 




Figure 6. MMP expression in different LE subtypes. (A) MMP-3 positive keratinocytes, fibroblasts and 
macrophages in DLE. (B) Expression of MMP-3 in UVA-photoprovocated skin. (C) MMP-7 expression in area 
of basal vacuolisation in SCLE. (D) MMP-9 is expressed by macrophages in SLE. (E) Abundant MMP-10 
expression in SCLE. (F) MMP-10-positive keratinocytes and fibroblasts in DLE. (G) MMP-26 is expressed in 
basal keratinocytes in SCLE. (H) TIMP-1 is expressed by occasional fibroblasts in DLE. (I) TIMP-3 is detected 
in basal and suprabasal keratinocytes and macrophages in DLE. 
 
 
(G) Epithelial MMP-26 expression was detected roughly in half of the samples studied in 
each group (Figure 6). Upregulated protein expression was not associated to inflammation as 
such, but in contrast to basal vacuolisation. Stromal expression was detected only in elastic 
fibres in the mid-dermis in accordance with previous findings in other skin disorders with 
solar damage (Ahokas et  al. 2005). Neither photoprovocated samples of healthy volunteers 
nor normal epidermis showed positive staining. (H) Some stromal expression of TIMP-1 was 
detected in fibroblasts. (I) In SCLE and SLE samples, TIMP-3 protein expression was seen in 




basal and suprabasal layers. Epithelial immunoreactivity was diminished in areas of 
inflammation and apoptosis, but was associated with keratinocyte proliferation. 
 
In  order  to  detect  proliferative  keratinocytes  (Impola et  al. 2003), MMP-19 was 
immunostained. In general, positive staining was observed throughout the basal layer of the 
epidermis (graphical data not shown). As expected, MMP-19 associated with proliferative 
cells,  and  was  also  often  seen  in  the  regions  of  basal  vacuolisation.  The  protein  seemed  to  
colocalise with MMP-10 in keratinocytes, although the expression of MMP-10 was more 
widely distributed. However, in DLE specimens MMP-3 and -26 were often also expressed in 
the same areas as MMP-19 positive cells, while TIMP-3 expression was somewhat wider. 
 
In contrast to epithelial cells, frequent expression of MMP-14 was detected in stromal cells, 
and  the  protein  was  expressed  in  almost  all  LE samples  by  fibroblasts  and  endothelial  cells  
(Figure 7 A). Sporadic colocalisation with apoptotic keratinocytes was also observed (Figure 
7 B). Keratinocytes in normal skin did not show positive staining, but occasional 
immunoreactivity was found in fibroblasts. Apoptotic cells were observed as often in the 
epithelium as in the stroma (Figure 7 B). Three quarters of DLE, SCLE and SLE samples had 
apoptotic epithelial cells. However, the average number of apoptotic keratinocytes was 




Figure 7. Colocalisation of MMP-14 with apoptotic basal keratinocytes in DLE. Arrows depict corresponding 






Table 14. Expression of different MMPs and TIMPs in samples from patients with DLE, SCLE or SLE. 
Lupus 
subtype 
MMP-3 MMP-7 MMP-9 MMP-10 MMP-14 MMP-19 MMP-26 TIMP-1 TIMP-3 
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In this doctoral study over 300 Finnish LE patients with cutaneous manifestations have been 
characterised clinically and screened for a panel of genes in order to unravel the so far largely 
unknown genetic background of CLE. In addition, Finnish families affected by SLE, as well 
as Swedish patients with distinct, but related connective tissue diseases and positive for 
Ro/SSA autoantibody typical for LE have been used to extend the patient material in order to 
replicate the original findings. The results demonstrate that in a clinical context, Finnish LE 
patients do not differ from other contemporary patients. However, DLE patients should be 
examined with care because of signs of within group heterogeneity. Importantly, we were 
able to show that genetic constitution is at least partially shared between clinically different 
entities with varying disease course. A subphenotype analysis carried out in a sufficiently 
large sample set is of value to shed more light on disease development in patients who suffer 
from specific and usually severe manifestations of LE, such as renal involvement. Finally, 
these studies address the importance of investigating gene-gene and gene-environment 
interactions, known confounding but understudied factors, underlying individual disease 
susceptibility. 
 
1 Clinical investigation of patients 
Our series of LE patients with cutaneous manifestations is one of the largest described in 
dermatological literature. Comprehensive studies investigating a wide spectrum of clinical 
and laboratory features of DLE and SCLE in particular are sparse, limited in sample size and 
patients may be missclassified (Wallace et al. 1992 and references therein). More studies have 
assessed the presence of cutaneous manifestions in SLE (Petri 1998; Yell et al. 1996 and 
references therein). However, many of them date back to 1960s and 1970s addressing the 
importance of our study in this field.  
 
In terms of cutaneous and visceral involvement, immunological and haematological findings, 
Finnish patients resemble those reported in the literature. Overlapping of cutaneous 
subphenotypes was frequently seen in patients with SLE. SLE patients presenting with skin 
lesions typical for DLE exceeded reported numbers (Petri 1998; Yell et al. 1996), while the 
prevalence of SCLE lesions in patients with SLE was consistent with the previous study (Yell 
et al. 1996). This may be partly attributable to our study inclusion criteria, the presence of 
LE-specific skin manifestations being a prerequisite for recruitment. Another explanation 
might be population differences. The Finnish population has been shown to differ from other 
Northern European populations and is suggested to have a distinct eastern contribution 
(Salmela et al. 2008). In their attractive report Chung et al. (2009) showed that Northern 
European ancestry is significantly associated with photosensitivity and discoid rash and 
suggested that variation in disease outcome is attributable to genetic ancestry. Furthermore, 
clinical manifestations in SLE are known to have broad geographic and ethnic variation, 





Patients with SCLE were characterised by increased levels of Ro/SSA and La/SSB 
autoantibodies, while such elevated titres were unusual in DLE patients, which agrees with 
previous studies (Lee et  al. 1994; Popovic et al. 2007a; Sontheimer 2005). Ro and La 
autoantibodies  were  displayed  with  similar  frequency  in  both  SCLE  and  SLE  as  reported  
previously (Chlebus et al. 1998). High levels of Ro autoantibodies are known to correlate 
with systemic inflammatory disease (Popovic et al. 2007a), while low levels of these 
autoantibodies at baseline indicate more favourable prognosis and disease condition limited to 
the skin (Popovic et al. 2008). Ro autoantibodies have been reported to associate with 
increased photosensitivity (McCauliffe 1997; Petri 1998)  and we noted a similar tendency. 
 
The immunological and haematological findings featured patients with SLE in accordance 
with other studies (Chlebus et al. 1998; Wallace et al. 1992). The prevalence of lymphopaenia 
and leukopaenia in SLE patients was different from that reported (Chlebus et al. 1998). The 
fact that our patients were recruited via dermatological services and ascertained for SLE 
through their skin symptoms may account for these differences. Indeed, the prevalence of 
leukopaenia was similar to that observed in verified CLE cohorts (Vera-Recabarren et al. 
2010; Wallace et al. 1992). 
 
The cluster analysis allocated DLE patients into three separate groups with clearly different 
clinical profiles (Figure 4): one group is defined by the presence of discoid lesions, while two 
other groups consist of patients with immunological abnormalities, some of which are known 
to predict an unfavourable prognosis (Popovic et al. 2007a; Tebbe et al. 1997). This scattering 
of patients implicates some heterogeneity in the DLE subtype and warrants regular evaluation 
to identify early patients with DLE who are at risk of developing SLE. Whether the observed 
heterogeneity is due to ambiguous diagnostic criteria or genetic heterogeneity remains to be 
elucidated. 
 
2 Genetic studies implicate shared predisposing genes for CLE and SLE 
In  Studies  II  and  III,  it  was  shown for  the  first  time that  IRF5 and TYK2 genes involved in 
type 1 IFN signalling contribute to CLE susceptibility. We further reproduced the association 
of IRF5 with SLE and more importantly, provided evidence supporting a role for TYK2. 
Before our study, only two groups have established an association (Graham et al. 2007; 
Sigurdsson et al. 2005), while single GWAS failed to support TYK2 as a susceptibility gene 
for SLE (Harley et al. 2008). 
 
The associated A allele at rs10954213 in IRF5 alters a polyadenylation site contributing to 
shorter and more stable mRNA and inducing higher IRF5 expression (Cunninghame Graham 
et al. 2007; Graham et al. 2007), thus likely leading to excessive production of type 1 IFNs. 
SLE patients bearing IRF5 risk haplotype display high serum IFN-  activity (Niewold et al. 
2008) that follow flares of disease activity and expression of external manifestations, such as 
skin rash and fever (Kozyrev and Alarcon-Riquelme 2007). Moreover, enhanced production 
of type 1 IFNs promotes inflammation in CLE through recruitment of T-cells into skin lesions 




and IRF5 is also critical regulator of DNA damage-induced apoptosis (Kozyrev and Alarcon-
Riquelme 2007). Taken together, this body of evidence supports the role of IRF5 not only in 
SLE but also in CLE pathogenesis. 
 
Out of the three studied markers in TYK2, rs2304256 associated to both DLE and SLE. The 
same marker accounted for strong association signal in the Scandinavian study (Sigurdsson et 
al. 2005). This missense variant results in an amino acid change of phenylalanine (A allele) to 
valine (C allele) within a larger JH4 domain crucial for the interaction of TYK2 with IFN-  
receptor and its function, and for maintaining expression of the receptor on cell membranes 
(Sigurdsson et al. 2005). Marker rs12720270 gave a significant signal only in SLE patients. In 
the UK SLE families, this variant was found to have the strongest association (Graham et al. 
2007), while it was not studied in Nordic families (Sigurdsson et al. 2005). Marker 
rs12720270 is situated close to an intron/exon boundary, suggesting a role for missplicing 
events in molecular pathogenesis (Graham et al. 2007). Neither CLE nor SLE patients 
showed association to rs1272036 in agreement with the UK study (Graham et al. 2007). 
Furthermore, a core associated region was identified in the UK study; both rs2304256 and 
rs12720270 are located within this region, while rs12720356 lies outside it (Graham et al. 
2007). Our results reinforce this observation further. Although functional studies are rare, the 
high level of sequence conservation suggests that TYK2 variants have an important role in the 
function of the protein (Graham et al. 2007). Interestingly, a truncated TYK2 protein was 
found in a patient with primary immunodeficiency syndrome, skin manifestations and defects 
in cytokine signalling (Minegishi et al. 2006). 
 
We further carried out a semi-quantitative analysis of IRF5 and TYK2 protein expression in 
skin specimens obtained from patients. Both showed positive staining in the upper 
keratinocyte layers and upregulated expression in dermal macrophage- and fibroblast-like 
cells. In addition, IRF5 was expressed in plasma cells in the dermis. Expression of IRF5 
detected in cultured keratinocytes (Akgul et al. 2006) supports our findings in skin samples. 
In  addition,  expression  of  IRF5  has  been  detected  in  B-cells  and  pDCs  (Kyogoku  and  
Tsuchiya 2007).  
 
In Study IV, we demonstrated a novel association between ITGAM variants and a cohort of 
patients  with  carefully  verified  DLE  (Table  11).  Patients  with  DLE  showed  a  remarkably  
strong association to ITGAM marker rs1143679, the highest P-value being 10-11 and three-fold 
increased risk compared to control individuals. A similar tendency was also observed in 
SCLE. In line with a recent study (Kim-Howard et al. 2009), a suggestive association was 
found between ITGAM and  a  subgroup  of  SLE  patients  with  malar  and/or  discoid  rash.  Of  
particular interest is the observation that risk estimates for DLE (OR 3.0) in our study were 
much higher than those reported for SLE (Han et al. 2009b; Harley et al. 2008; Hellquist et 
al.; Hom et al. 2008; Nath et al. 2008) or for SLE patients with discoid rash (Kim-Howard et 
al. 2009) in European-derived populations. When MAFs were compared between different 
forms of LE in our study, DLE patients showed a clear enrichment of risk alleles compared to 




SLE patients with discoid rash (Kim-Howard et al. 2009). Taken together, our results support 
the putative role of ITGAM gene in DLE pathobiology. 
 
The exon three variant rs1143679 was originally described simultaneously by two GWASs 
(Harley et al. 2008; Hom et al. 2008) and one candidate gene study following a genome-scan 
(Lee and Nath 2005; Nath et al. 2008). To date, the unambiguous association of rs1143679 
with SLE has been confirmed in a meta-analysis encompassing different ethnicities (Han et 
al. 2009b). A successful replication study has also been performed in Finnish SLE patients 
(Hellquist et al.). However, attempts to replicate the association for rs1143679 in Chinese 
(Han et al. 2009a),  as  well  as  Japanese  and  Korean  (Kim et al. 2009), patients have failed, 
suggesting true genetic heterogeneity in disease susceptibility between European and non-
European populations. Interestingly, the frequency of the risk allele A at rs1143679 has been 
shown to increase with higher levels of European ancestry (Molineros et al. 2009).  
 
There are several disease contributing variants within the ITGAM and the nearby ITGAX gene 
(Harley et al. 2008; Hom et al. 2008; Nath et al. 2008) (Table 11). It has been speculated that 
these additional association signals mirror only the strong LD between rs1143679 and 
adjacent markers (Han et al. 2009b), as any haplotype carrying the risk allele A at rs114367 
within ITGAM confers  risk  for  SLE (Nath et  al. 2008). Due to the tight LD in the ITGAM-
ITGAX region, it is not possible to determine the actual causal gene, but current evidence does 
not support an independent role of ITGAX (Han et al. 2009b; Hom et al. 2008). 
 
ITGAM encodes for a cell surface receptor expressed on neutrophils, macrophages and 
dendritic cells (Hom et  al. 2008). The only ITGAM variant  for  which  a  functional  role  has  
been proposed to date is rs1143679. This polymorphism results in an amino acid change 
(R77H) predicted to alter the structure and function of the protein and influence the 
conformation  of  a  domain  to  which  many  ligands  do  bind  (Nath et  al. 2008). Based on its 
functions, ITGAM may predispose to DLE through impaired uptake of apoptotic cells or 
immune complexes, altered ICAM-1 mediated leukocyte trafficking (Rhodes and Vyse 2008) 
or defective immune suppression in UV-exposed skin (Hammerberg et al. 1998; Kang et al. 
1998; Takahara et al. 2003).  
 
2.1 Sjögren’s syndrome and ITGAM (unpublished data) 
SS is a disease that shares similar features with SLE (Espinosa et al. 2006) and for which only 
a few genes have been discovered (Korman et al. 2008; Miceli-Richard et al. 2007). The 
syndrome may occur alone, termed as primary SS, or together with other rheumatic diseases, 
like SLE and is then defined as secondary SS (Espinosa et al. 2006). We tested ITGAM for 
association in the subgroup of Finnish and Swedish patients having SS and found a 
moderately increased disease risk compared to control individuals. However, our sample set 
may have been somewhat heterogeneous, given that in Finnish patients SS was secondary to 
LE,  whereas  most  Swedish  patients  had  primary  SS,  thus  counfounding  the  analysis.  




underlying LE. Nevertheless, we are the first to show that ITGAM may predispose to other 
autoimmune diseases than LE and have a more general role in these diseases. 
 
3 GWAS-identified SLE susceptibility genes implicate possible new pathways in CLE 
(unpublished data) 
We also screened a group of 13 genes identified in GWASs (Graham et al. 2008; Harley et al. 
2008; Hom et  al. 2008; Kozyrev et al. 2008) for disease association in LE patients with 
cutaneous manifestations. We could replicate findings for STAT4, TNFAIP3, IRF5-TNPO3 
and BLK-FAM167A in SLE (Table 13). In addition to these genes, the 1q25.1 locus and 
BANK1 gene gave a significant signal in DLE. High LD exists at  the corresponding genetic 
regions which hampers the identification of true causative SNPs that are responsible for the 
observed associations. According to the criteria set by Graham et al. (2009), today all the 
aforementioned genes are considered validated SLE susceptibility genes. However, to our 
best knowledge, none of these genes have been implicated in DLE (or SCLE) before and 
warrant further confirmatory studies in larger patient cohorts from different populations. A 
functional role has already been assigned for some SNPs in BLK, BANK1, STAT4 and IRF5 
(Appendix Table 2) (Abelson et al. 2009; Graham et al. 2007; Hom et al. 2008; Kozyrev et 
al. 2008; Sigurdsson et al. 2008a; Sigurdsson et al. 2008b).  
 
The genes PXK, ATG5, ICA1, XKR, LYN, KIAA1542 and SCUBE1 originally showed only a 
suggestive  association  to  SLE  in  one  GWAS  (Harley et al. 2008) and did not demonstrate 
association to either DLE or SLE in our study. Out of these genes, PXK and ATG5 have been 
confirmed in SLE susceptibility (Graham et al. 2009). Only LYN has an assigned function in 
B-cell signalling (Harley et al. 2008), whereas others have no relation to immune functions or 
their function is completely unknown (Moser et al. 2009).  
 
Our results are in agreement with P-values and ORs reported previously. The highest ORs 
were found in TNFAIP3 in both DLE and SLE. However, large CIs compared to other genes 
indicate insufficient power to detect association at this locus. Although our SLE sample set 
was small (n=85), the majority of the association signals remained after correction for 
multiple testing. A potential undetected population stratification that may lead to spurious 
associations could be ruled out after performing a family-based association test (A. Hellquist, 
unpublished data). 
 
Based on these findings, two conclusions can be made. Firstly, BLK and BANK1 implicate a 
new biological pathway, namely lymphocyte signalling, in DLE pathogenesis, while STAT4 
and IRF5-TNPO3 genes support the role for type 1 IFN signalling (Harley et al. 2009; Moser 
et al. 2009). The SCLE sample set clearly suffered from lack of adequate statistical power, as 
only two markers in the IRF5-TNPO3 region were found to be associated. Nevertheless, 
together with the results obtained in Study II, this observation further supports the role of 
IRF5 also  in  SCLE  pathobiology.  Secondly,  SLE  patients  ascertained  through  cutaneous  




predisposition than do patients verified through other ACR criteria (Graham et  al. 2008; 
Harley et al. 2008; Hom et al. 2008; Kozyrev et al. 2008). 
 
4 Gene-gene interaction 
The existence of gene-gene interaction, or epistasis, has been long recognised, but very little 
effort has been made to address this phenomenon in SLE mainly due to methodological 
limitations. Additive effects (i.e. proportional increase in risk) have been more feasible to 
assess in individuals carrying multiple risk alleles for IRF5 and STAT4 (Abelson et al. 2009; 
Sigurdsson et al. 2008b),  both members of the type 1 IFN pathway. We therefore set  out to 
test a possible interaction between SNPs in IRF5 and TYK2,  another  member  of  the  type  1  
IFN pathway. Of note, an overall interaction reaching statistical significance was detected 
between rs10954213 in IRF5 and rs2304256 in TYK2 (Figure  5).  Interpretation  of  OR  data  
clearly shows that by combining risk genotypes of each respective SNP, the risk of disease 
increases significantly. It is tempting to speculate that the switching of phenylalanine (A 
allele) to valine (C allele) in TYK2 in combination with altered IRF5 mRNA properties 
(encoded by rs10954213) has functional relevance in the pathogenesis of SLE. Interestingly, 
the IRF5 SNP rs10954213 was observed to interact with HLA alleles in psoriasis, a disease 
that shares inflammatory features with SLE (Sanchez et al. 2008). None of the robust 
associations exhibited evidence of gene-gene interaction in a GWAS (Hom et al. 2008). This 
may be a consequence of limited power to detect multidimensional modes of interaction or 
simply because of stringent statistical thresholds set for multiple testing (Altshuler et al. 
2008). Based on estimations (Gauderman 2002), our sample size (n=277) can be considered 
sufficient enough to obtain adequate power for detecting epistatic effects between genes that 
have relative strong interaction, such as IRF5 and TYK2. Larger sample size is undoubtedly 
needed to observe more modest or multidimensional interactions. These observations should 
encourage investigators to further study the interactions between LE susceptibility genes in 
order to elucidate the biological and biochemical networks that underpin disease; both 
statistical framework (Cordell 2009) and patient cohorts sufficient in numbers are available. 
 
5 Smoking as an indicator of possible gene-environment interaction 
Tobacco smoking at the onset of disease was a very common habit in our patient series and 
the prevalence of smokers significantly exceeded that of the general Finnish population (22%) 
(Statistics Finland 2005). The number of smokers was particularly pronounced among DLE 
patients. Interestingly, with cluster analysis it became evident that smoking is involved in the 
development of DLE, while immunological factors were more significant in the outbreak of 
SLE. These observations suggest that smoking might be one of the possible triggering factors 
in the development of LE. Cigarette smoking has been causally linked to the development of 
autoimmune diseases, such as RA and Graves disease (Costenbader and Karlson 2006) as 
well as LE (Boeckler et al. 2009; Costenbader et al. 2004; Gallego et al. 1999; Lipsker et al. 
2006; Miot et al. 2005). Furthermore, smoking is known to increase cutaneous damage in LE 
(Freiman et al. 2004; Turchin et al. 2009). There are many proposed mechanisms (Boeckler et 




has emerged. Cigarette smoke contains numerable noxious and toxic chemicals that have the 
potential to interact with DNA, causing genetic mutations and gene activation (Costenbader et 
al. 2004). It is possible that individual responses to these insults are genetically determined, or 
that cigarette smoking may be synergistic with other environmental exposures. Our 
observations raise the possibility of gene-environment (tobacco) interaction especially in the 
development of CLE. Polymorphisms in detoxifying GST enzymes have been associated to 
CLE (Millard et al. 2008) and this family of enzymes has already demonstrated gene-
environment interaction in SLE (Fraser et al. 2003; Karlson et  al. 2007). Moreover, it has 
been shown that these enzymes influence the number of DNA adducts, chromosomal breaks 
and tobacco consumption (Jourenkova et al. 1998; Piipari et  al. 2003; Tuimala et al. 2004) 
that may have pathological consequences. In terms of their function, GST loci are putative 
candidates for further studies. Recent investigations in Japanese SLE patients have implicated 
two other candidate genes that may modify the disease risk in smokers (Kiyohara et al. 2009a; 
Kiyohara et al. 2009b). A gene-environment interaction between smoking and HLA-DR genes 
has been proposed in the aetiology of RA (Klareskog et  al. 2006; Padyukov et al. 2004). 
Given the low heritability (Lawrence et al. 1987) it is of importance to address the impact of 
environmental factors and gene-environment interaction in CLE pathogenesis. Studying gene-
environment interactions has been regarded as a laborious task (Jonsen et al. 2007). However, 
an efficient approach for detecting interacting loci and being robust for changes in 
environmental exposures has been introduced recently (Murcray et al. 2009). 
 
6 Subphenotype analyses 
Clinical manifestations of LE are diverse and variable, both in individual patients and over 
time. Hence, a subphenotype (or endophenotype) analysis may provide insights into genetic 
factors that contribute to the overwhelming clinical diversity. Indeed, early linkage studies in 
SLE have provided a series of genetic effects that are derived from subsets of lupus including 
nephritis and smoking (reviewed in Harley et al. 2006). Thus far three studies have explored 
ITGAM and nearby ITGAX polymorphims for association to an array of features comprising 
the ACR criteria (Hom et al. 2008; Kim-Howard et al. 2009; Yang et al. 2009). These studies 
have found enrichment of ITGAM-ITGAX risk  alleles  in  SLE  patients  with  cutaneous  
involvement, immunological and haematological abnormalities, renal disease and 
neurological disorders. In line with this, we observed suggestive association between ITGAM 
and renal  involvement  in  SLE patients.  Furthermore,  Finnish  and  Swedish  patients  carrying  
ITGAM risk variants and being positive for Ro/SSA autoantibodies showed significantly 
increased disease risk in accordance with a previous Asian study (Yang et al. 2009). 
 
TYK2 gene is located on chromosome 19p13.2 that has been linked to the presence of dsDNA 
autoantibodies (Namjou et al. 2002b) and there is some evidence that IFN-inducible genes are 
upregulated in SLE patients who have manifestations of renal or central nervous system 
disease or haematological aberrations (Baechler et al. 2003). Many attempts, including ours, 
have been made to investigate IRF5 and TYK2 in clinical subgroups without any clearcut 





CTLA4 has been associated to a wide range of autoimmune diseases (Graham et al. 2006). No 
independent allele association was seen in CLE patients, but one haplotype, GGCGA, showed 
over two-fold increased risk in a small fraction of DLE patients that were investigated further. 
Of particular interest, patients with GGCGA haplotype were more often men, smoking at 
disease onset and had low C3 values more often than those DLE patients without the GGCGA 
haplotype. As discussed earlier, smoking is a putative trigger factor for DLE and the 
prevalence of smoking is high among our DLE patients. One may hypothesise that smoking, 
together with other environmental factors and the high risk haplotype, triggers the disease 
especially in men. In fact, a combination of complement deficiency and high frequency of 
smoking has been described in male patients with DLE (Boeckler et al. 2005). 
 
Subphenotype analyses are of importance to detect clinical subgroups not previously 
recognised to be significant and may improve weak associations when multiplex pedigrees or 
case-only material are stratified by specific phenotype (Cardon and Bell 2001). Unfortunately, 
the cost of genetic homogeneity of a study cohort is often reduced statistical power to detect 
associations. Applying a larger number of patients has proven to be beneficial for elucidating 
the relationship between manifestations of SLE and variations in ITGAM as  well  as  STAT4 
genes (Hellquist et al. 2009; Kim-Howard et al. 2009; Sigurdsson et al. 2008b; Taylor et al. 
2008). However, a subphenotype approach may be statistically hazardous (Cardon and Bell 
2001). A common error is to analyse the patient population repeatedly using different clinical 
phenotypes or genotypically defined subgroups. Multiple testing provides less robust results 
and increases a type 1 error. Moreover, it has been shown that the European population 
substructure influences several manifestations seen in SLE patients and genetic studies of 
subphenotypes should carefully address issues of population substructure based on genetic 
ancestry (Chung et al. 2009). 
 
7 Matrix metalloproteinases as mediators of tissue injury 
Specific MMPs and their endogenous inhibitors, TIMPs, have been implicated in the 
pathobiology of SLE, but their contribution to tissue damage in cutaneous forms of lupus has 
not been studied. In Study V, we focused especially on MMPs known to regulate apoptosis 
and induced by UV light. MMPs-3, -10, -14 and -26 were abundantly expressed by 
keratinocytes in DLE, SCLE and SLE skin specimens. None of these proteins is present in 
normal skin, but rather require wounding or tumourgenesis for induction (Ahokas et al. 2005; 
Karelina et al. 1994; Kerkela et al. 2001; Ohnishi et al. 2000). 
 
UV radiation is known to induce the expression of MMP-7 and -12 in healthy skin (Saarialho-
Kere et al. 1999) and MMP-10 in cultured keratinocytes (Dazard et al. 2003). However, 
photoprovocation did not upregulate MMP-10 or -26 expression in the skin of healthy 
volunteers. Therefore mere UV radiation is probably not the triggering factor for these 
enzymes in keratinocytes of LE skin. In wounded skin, tightly regulated expression and 
localisation of MMP-10 is required for organised matrix degradation and keratinocyte 
migration (Krampert et al. 2004). During impaired wound healing the expression of this 




expression may contribute to the aberrant matrix degradation seen in LE patients. In poorly 
healing wounds the balance between metalloenzymes, such as MMP-10, and their inhibitor 
TIMP-1 is disturbed (Vaalamo et al. 1996).  This  might  be  the  case  in  LE  lesions  as  well,  
because  only  sparse  dermal  TIMP-1  expression  was  seen  in  our  samples.  MMP-26  was  
expressed in the areas of basal destruction and in line with a previous report (Ahokas et al. 
2005) can thus be upregulated by altered cell-matrix interactions or changes in the cytokine 
milieu. 
 
Apoptosis may play an important role in the evolving skin lesions of LE. In agreement with 
previous studies (Baima and Sticherling 2001; Kuhn et al. 2006), we observed apoptotic 
keratinocytes in the upper as well as in basal and suprabasal layers of the epidermis. As 
shown before (Kuhn et al. 2006), no considerable difference in the number of apoptotic nuclei 
in lesional skin was evident between different diagnostic groups. MMP-14 may drive 
apoptosis in endothelial cells (Mandel et al. 2004) and regulate the survival of epithelial cells 
(Nagavarapu et al. 2002). Consistent with this, MMP-14 was occasionally detected in the 
apoptotic areas. Although previously implicated in the regulation of apoptosis (Tsukinoki et 
al. 2004), we were not able to detect MMP-7 in such regions. Instead, epithelial expression of 
MMP-7 was detected in keratinocytes in regions of basal membrane vacuolisation especially 
in acute forms of the disease, namely SCLE and SLE. MMP-7 degrades many components of 
the  cell  matrix  (McCawley  and  Matrisian  2001),  thus  altered  cell-cell  contacts  could  be  
inducing it even in benign epidermis. Unlike in graft-versus-host disease (Salmela et al. 
2003), TIMP-3 did not either colocalise with apoptotic areas. In general, TIMP-3 was 
abundantly expressed in samples in agreement with a gene array study (Rus et al. 2004). 
 
These results demonstrate that DLE, SCLE and SLE do not differ in their MMP expression 
profile. Low expression of TIMP-1 implicates that involved skin is characterised by 
proteolytic events and that MMPs function in LE skin without impedance from their 
inhibitors. These data, in agreement with gene array studies carried out in patients with SLE 
(Mandel et al. 2004), suggest that specific MMPs should be targeted for therapeutic action as 





CONCLUSIONS AND FUTURE PROSPECTS 
 
When I started my doctoral studies in 2006, I never would have believed how rapid the 
technological development would be during the next four years. Genetic research was just 
heading toward genome-wide SNP genotyping, which was considered to be a demanding task. 
Today, it is possible to genotype a million SNPs in one individual at a time. These advances 
are reflected by an increasing number of genes identified to underlie SLE susceptibility. At 
the same time, little is known about the genetic architecture of the cutaneous forms of similar 
diseases, namely DLE and SCLE. 
 
To unravel the genetic background of CLE, over 300 patients with predominant cutaneous 
manifestations were recruited through dermatological practices and ascertained carefully for 
clinical, immunological and haematological features as a basis for genetic studies. When these 
clinical characteristics were compared with those reported in the literature, no obvious 
differences were found. Cigarette smoking featured especially in patients with DLE, 
implicating a role for smoking in disease aetiology.  
 
Before us, only one small candidate gene study had been accomplished that demonstrated 
association to genes harbouring the HLA region (Millard et al. 2001). These doctoral studies 
are  the  first  to  screen  a  wide  array  of  candidate  genes  in  CLE.  As  a  result,  we  added  novel  
genes ITGAM, IRF5 and TYK2 to the short list of genes shown to be associated with CLE. In 
addition, many more genes known to associate with SLE were found to increase the risk of 
CLE, which also implicated new disease pathways. ITGAM confers a remarkably higher risk 
for DLE than for SLE and is an intriguing novel susceptibility gene based on its functions in 
phagocytosis and UV-induced immune suppression. Our results are in line with reports 
demonstrating an even stronger association in SLE patients stratified for discoid lesions (Kim-
Howard et al. 2009). IRF5 and TYK2 genes are involved in IFN signalling thus supporting the 
role of type 1 IFNs in skin inflammation. When patients were grouped according to 
subphenotypes, such as renal involvement and immunological abnormalities, no significant 
genetic associations were found. Subphenotype analyses aim to shed light on the 
overwhelming phenotypic heterogeneity of LE, but have not been successful until recently 
with the increase of sample sizes. 
 
Many of the genes studied here were originally identified through GWASs conducted in SLE 
patients. GWASs have been critisised for focusing on populations of European ancestry. 
Therefore it is important to replicate the present findings in other ethnicities to unambigiously 
identify causative variants. It has already been shown that ITGAM does not confer 
susceptibility in a Chinese population (Han et al. 2009a) and increase in risk allele 
frequencies is associated with higher levels of European ancestry (Molineros et al. 2009). 
STAT4 seems  to  have  a  similar  strength  of  association  across  multiple  racial  groups  
(Kobayashi et al. 2008; Namjou et al. 2009). Furthermore, large enough sample sizes are 
required for detecting statistically robust associations. It has been estimated that as many as 




frequency  of  20%  and  an  OR  of  1.2  (Altshuler et  al. 2008). The success made in the 
identification of SLE susceptibility genes would not have been possible without research 
consortiums. Similar broad level collaboration is needed to elucidate the genetic background 
of CLE. This would also help to assess the impact of genes in specific clinical subphenotypes, 
such as patients with renal involvement or specific immunological abnormalities. 
 
The basic idea behind genetic mapping is not primarily risk prediction, but rather to 
understand the mechanisms underlying a specific disease, and for CLE these mechanisms are 
poorly known. The novel predisposing genes ITGAM, IRF5 and TYK2 identified in these 
doctoral studies all fall in key immunological pathways and provide some insights to the 
pathobiology. In addition, these pathways are good targets for therapy and, for instance, 
therapeutic modulation of type 1 IFN signalling might have a beneficial impact on LE-
specific skin disease (Walling and Sontheimer 2009). Hereditability estimates for DLE 
implicate that environmental triggering factors have a substantial role in disease development. 
Therefore, it would be interesting to know how these genes respond to environmental stimuli 
such as UV light and tobacco smoke. With the aid of new parallel sequencing methods it is 
even possible to screen for the whole expression profile after an environmental challenge. 
Taken together, this doctoral study, incorporating careful clinical evaluation of LE patients 
with cutaneous manifestations and systematic genetic analyses, has contributed to our 
understanding of the genetic architecture and putative pathological pathways of this disease 






Table 1. The genes and their respective SNPs showing either linkage or association to 
SLE and selected for genotyping in Finnish CLE and SLE patients (Studies II and III). 






PTPN22 rs2476601 1 114,179 Coding (R620W) 
Binding affinity 
(Kaufman et al. 2006) SR<85% 
CRP rs1205 1 157,948 Gene expression (Russell et al. 2004) SR<85% 
FCGR2A rs1801274 1 159,746 Coding (H167R) 
Receptor binding 
affinity 
(Karassa et al. 2002; 




2 204,440 Coding (T17A) (Graham et al. 2006)  
CTLA4 rs3087243 
(CT60) 
2 204,447 Unknown   
CTLA4 rs231726 2 204,449 Unknown   
CTLA4 rs231727 2 204,449 Unknown   
CTLA4 rs1991416 2 204,463 Unknown   
PDCD1 rs11568821 2 242,442 TF binding site (Prokunina et al. 2002; 
Sigurdsson et al. 2005) 
 
IRF5 rs2004640 5 128,365 Splice site (Graham et al. 2007; 
Sigurdsson et al. 2005) 
SR<85% 
IRF5 rs10954213 5 128,376 Polyadenylation   
TNF-  rs1800630 6 31,650 Unknown (Suarez et al. 2005; van 
Heel et al. 2002) 
Assay design failed 
TNF-  rs1800629 
(-308A) 
6 31,651 Gene expression  Assay design failed 
GIMAP5 rs759011 7 150,070 Unknown (Hellquist et al. 2007) Genotyped only in  
GIMAP5 rs1046355 7 150,070 Unknown  case-control 
GIMAP5 rs6598 7 150,071 Polyadenylation  material 
GIMAP5 rs2286899 7 150,071 Splice site   
NOD2 rs2066843 16 49,302 Unknown (De Jager et al. 2006; 
Duerr et al. 2006) 
SR<85% 
NOD2 rs2066845 16 49,314 Coding (G908R)  Monomorphic 
NOD2 rs2076756 16 49,314 Unknown  Genotyped only in 
family material  
TYK2 rs12720270 19 10,336 Unknown (Graham et al. 2007; 
Sigurdsson et al. 2005) 
 
TYK2 rs2304256 19 10,336 Coding (V362F)   
TYK2 rs12720356 19 10,330 Coding (I684S)   
CRP, C-reactive protein, pentraxin-related; CTLA4, cytotoxic T-lymphocyte-associated protein 4; FCGR2A, Fc 
fragment of IgG, low affinity IIa, receptor (CD32); GIMAP5, GTPase, IMAP family member 5; IRF5, interferon 
regulatory factor 5; NOD2, nucleotide-binding oligomerization domain containing 2; PDCD1, programmed cell 
death 1; PTPN22, protein tyrosine phosphatase, nonreceptor type 22; TNF- , tumour necrosis factor alpha (TNF 
superfamily, member 2); TYK2, tyrosine kinase 2 




Table 2. The eleven ITGAM markers and additional GWAS-identified genes selected for 
genotyping in Finnish CLE patients and Swedish patients positive for Ro/SSA-autoantibodies 
(Study IV and unpublished data). 





ITGAM rs1143679 16 31,184 Coding (R77H) (Nath et al. 2008)  
 ITGAM rs9936831 16 31,194 Unknown (Nath et al. 2008)  
ITGAM rs9937837 16 31,206 Unknown (Hom et al. 2008)  
ITGAM rs9888879 16 31,217 Unknown (Nath et al. 2008)  
ITGAM rs12928810 16 31,219 Intronic   
ITGAM rs9888739 16 31,220 Unknown (Nath et al. 2008)  
ITGAM rs11860650 16 31,234 Unknown (Nath et al. 2008)  
ITGAM rs6565227 16 31,236 Intronic (Nath et al. 2008) SR<85% 
ITGAM rs1143678 16 31,250 Coding (P1146S) (Harley et al. 2008) SR<85% 
ITGAM rs4548893 16 31,271 Unknown (Harley et al. 2008)  
ITGAM rs11574637 16 31,276 Unknown (Hom et al. 2008)  
Additional markers       
1q25.1 rs10798269 1 171,576 Unknown (Harley et al. 2008)  
STAT4 rs3821236 2 191,611 Regulatory# (Graham et al. 
2008)  
 
STAT4 rs7601754 2 191,648 Unknown (Harley et al. 2008)  
STAT4 rs7574865 2 191,672 Regulatory# (Harley et al. 2008; 
Hom et al. 2008) 
 
STAT4 rs10181656 2 191,678 Regulatory# (Remmers et al. 
2007) 
 
STAT4 rs7582694 2 191,678 Regulatory# Prof. Ann-Christine 
Syvänen 
 
PXK rs6445975 3 58,466 Unknown (Harley et al. 2008)  
BANK1 rs10516487 4 102,970 Coding (R61H) (Kozyrev et al. 
2008) 
 
ATG5 rs573775 6 106,871 Unknown (Harley et al. 2008)  
TNFAIP3 rs6920220 6 138,048 Unknown (Graham et al. 
2008) 
 
TNFAIP3 rs10499197 6 138,174 Unknown (Graham et al. 
2008) 
 
TNFAIP3 rs5029939 6 138,237 Unknown (Graham et al. 
2008) 
 
TNFAIP3 rs2230926 6 138,237 Coding (F127C) (Graham et al. 
2008) 
 
TNFAIP3 rs7749323 6 138,272 Unknown (Graham et al. 
2008) 
 
ICA1 rs10156091 7 8,153 Unknown (Harley et al. 2008)  








Table 2 continues 





IRF5-TNPO3 CGGGG indel 7 128,365 Regulatory* (Sigurdsson et al. 
2008a) 
 
IRF5-TNPO3 rs3807306 7 128,367 Unknown (Cunninghame 
Graham et al. 
2007) 
 
IRF5-TNPO3 rs2070197 7 128,376 Unknown (Graham et al. 
2007) 
 
IRF5-TNPO3 rs10488631 7 128,381 Unknown (Graham et al. 
2007; Hom et al. 
2008) 
 
IRF5-TNPO3 rs2280714 7 128,381 Unknown (Cunninghame 
Graham et al. 
2007) 
 
IRF5-TNPO3 rs12539741 7 128,384 Unknown (Harley et al. 2008)  
IRF5-TNPO3 rs10279821 7 128,470 Unknown (Harley et al. 2008)  
IRF5-TNPO3 rs12537284 7 128,505 Unknown (Harley et al. 2008)  
XKR6 rs6985109 8 10,798 Unknown (Harley et al. 2008)  
XKR6 rs4240671 8 10,805 Unknown (Harley et al. 2008)  
XKR6 rs11783247 8 10,826 Unknown (Harley et al. 2008)  
XKR6 rs6984496 8 10,833 Unknown (Harley et al. 2008)   
BLK-FAM167A rs2736340 8 11,381 Unknown (Hom et al. 2008)  
BLK-FAM167A rs13277113 8 11,386 Regulatory# (Hom et al. 2008)  
BLK-FAM167A rs4840568 8 11,388 Unknown (Hom et al. 2008)  
BLK-FAM167A rs2618476 8 11,389 Unknown (Graham et al. 
2008) 
 
BLK-FAM167A rs2248932 8 11,429 Unknown (Harley et al. 2008)  
LYN rs7829816 8 57,011 Unknown (Harley et al. 2008)  
LYN rs2667978 8 57,060 Unknown (Harley et al. 2008)  
KIAA1542 rs4963128 11 579,6 Kb Unknown (Harley et al. 2008)  
SCUBE1 rs2071725 22 41,939 Unknown (Harley et al. 2008)  
ATG5, ATG5 autophagy related 5 homolog; BANK1, B-cell scaffold protein with ankyrin repeats 1; BLK, B 
lymphoid tyrosine kinase; FAM167A, family with sequence similarity 167, member A; ICA1, islet cell 
autoantigen 1, 69kDa; IRF5, interferon regulatory factor 5; ITGAM, integrin alpha M; KIAA1542, PHD and ring 
finger domains 1; LYN, v-yes-1 Yamaguchi sarcoma viral related oncogene homolog; PXK,  PX  domain  
containing serine/threonine kinase; SCUBE1, signal peptide, CUB domain, EGF-like 1; STAT4, signal transducer 
and activator of transcritption 4: TNFAIP3, tumour necrosis factor- -induced protein 3; TNPO3, transportin 3; 
XKR6, XK, Kell blood group complex subunit-related family, member 6 
Kb, kilobases; Mb, megabases; SR, success rate 
#Gene expression is correlated with SNP. 
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